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Abstract 
Tubedown (Tbdn), a developmentally regulated gene, is a subunit of the N-terrninal 
acety I transferase Arrest Defective-! (Ard 1) complex that is conserved from yeast to 
hun1an. The role of the Tbdn gene product was examined in the development and 
progression of pediatric neuroblastic tun1ors (ganglioneuroma, ganglioneuroblastoma, 
and neuroblastoma) that result from a blockage during normal sympathetic development. 
Currently, very few markers have been proven useful to distinguish the various states of 
neuroblastic differentiation. Therefore, the use of a neuroblastic tissue microarray was 
essential in determining the importance of Tbdn expression as a novel biomarker. High 
levels of Tbdn expression correlated with advanced tumor stages (stage 3 and 4), high-
risk group status, unfavorable histology, and poor outcome. 
In addition, the ftmctional relationship between the NatA complex (Tbdn and Ard 1) and 
the MycN gene product was investigated. MYCN gene amplification strongly correlates 
with advanced tumor stage and treatment failure. Although, MYCN gene amplification 
usually results in high MycN mRNA and protein expression there are subsets of 
neuroblastomas that have high MycN expression without MYCN gene amplification. I 
have demonstrated a co-regulation between Tbdn, Ardl, and MycN, using an in vitro 
human neuroblastoma LA-N-5 cell model. Subsequently, a conditional in vitro MycN-
inducible system demonstrated an over-expression of MycN that resulted in increased 
11 
expression of both Tbdn and Ardl. These results suggested that MycN may regulate the 
NatA complex. Promoter region analysis of TBDN and ARDI revealed a MycN 
consensus binding site within the TBDN promoter region, indicating a possible direct 
target for MycN. However, no MycN consensus sequence was detected within the ARDI 
promoter. The binding of MycN to TBDN was confirmed by chromatin 
immunoprecipitation potentially providing a mechanistic role for poor outcome in 
neuroblastoma. Finding functional links between MycN and TBDN will provide further 




I would like to thank my supervisors, Drs. Helene Paradis and Robert Gendron for the 
opportunity and experience of working on a great project and their guidance throughout 
my training; 
I am grateful to my supervisory committee, Drs. Laura Gillespie and Jules Dore for their 
guidance and support throughout my graduate program; 
I am appreciative to my present lab members (Ewa, Jackie, and Maria) and my past lab 
members (Stephanie, Adam, Dana, Karina, Thasin, Mandy, Christina, Mike, William, 
Lisa, Lacey, Genevieve, and Catherine) for their wisdom, discussions, and entertainment; 
I would like to thank Charlene and Janine for our weekly graduate course meetings; Neva 
for being a motivational writing partner; and Beth for being a straight-talker; 
I would also like to thank the 5th floor Cancer & Development group (Danielle, Nicole, 
Andrea, Nicole, Chris, Trina, Bryan, Pia, Joy, Mandy, and Brandon) for the social 
functions and everyday chitchats; 
I would also like to express gratitude to the faculty, staff, technicians and secretaries that 
have shape my learning experience; 
I am grateful to my family for their encouragement throughout my program; 
I want to express much appreciation to Lisa for her continued support in pursuing my 
aspirations. 
Five screws + One exercise ball + One laptop (minus 8 broken keys and 3 dismantles) + 
14 binders of data = one priceless journey 
lV 
----- - ----------~ 
Table of Contents 
ABSTRACT ......................................................................................................................................................... 11 
ACKNOWLEDGEMENTS ............................................................................................................................. IV 
TABLE OF CONTENTS ................................................................................................................................... V 
FIGURES .......................................................................................................................................................... VII 
TABLES .............................................................................................................................................................. IX 
ABBREVIATIONS ............................................................................................................................................. X 
1.1 CANCER ....................................................................................................................................................... 1 
1.2 NEUROBLASTIC TUMORS .................................................................................................................... 4 
1.3 NEUROBLASTOMA .................................................................................................. ................................ 5 
1.3.1 SPONTANEOUS R EGRESSION & APOPTOSIS .......... ... .. .... .. ...... ... .. ........... ......... ...... ... ... ..... ... .. ... .. .. .. .... . 8 
1.3 .2 EPIDEMIOLOGY ................................................... .. ...... .. .. .... .. ................ ....................... ...................... 13 
1.3.3 GENETIC PREDISPOSITION ...... ... ... .... .. ... .... ....... ...... .. . ...... ............ .... ......... ... .. .............. ...................... 14 
1.3 .4 NEURAL CREST D EVELOPMENT ...... ........ .. ... ................................ .... ..... .. ..................................... .. ... 16 
1.3.5 BIOLOGICAL PATHWAYS ............................ ... .. .. ... ....... .......... .. ............. .. ......... ...... .. .......................... 16 
1.3.6 MYCFAMILY .... ....... .. ...... ....................... .. .................................. .... .. .............. ... .... .......... .... .. ....... ..... l8 
1.3.7 CHROMOSOMAL AB ERRATIONS .. ............. ... .... ........... ........................................... .. .. .. .... ............ ...... 28 
1.3.8 DIFFERENTIATION .... .. .... .. .... ................................... ........ ..... ..................... .. .... .. ........... ... ................... 29 
1.3.9 HISTOLOGY .... ..... ... .. .. .. . ........ .. ............... .... ..... ... .... ... ...... ..... ................. ........ .......... ..... ... ....... ....... .. ... 30 
1.3. 1 0 DIAGNOSIS ............................... ............... .... ......... ..... ......... ....... ...................... .. .... ............ ... .. .. ...... .... 33 
1.3 .11 CLASSIFICATION ............. .... ... .. ...... .. .... .............. .. .... .... .......... .... .. .... ............ .................... ... ............ ... 34 
1.3. 12 TREATMENT ........ ....... .. ..... ... .... .............. .......... .... .. ...... ..... ............................. ........... .. ............. ... ... .... 41 
1.4 TUBEDOWN .............................................................................................................................................. 44 
1.5 HYPOTHESIS & OBJECTIVES ............................................................................................................ 52 
2.1 TUBEDOWN EXPRESSION CORRELATES WITH THE DIFFERENTIATION STATUS 
AND AGGRESSIVENESS OF NEUROBLASTIC TUMORS .................................................................. 53 
2.1.1 AUTHORS' CONTRIBUTION ... ........ ..... .... .... .. ...... ......... .................... .. .. ...... .... ..... .... ........... .. .......... .. .. 54 
2. 1.2 ABSTRACT .......... .. ...... .. ..... .... .... ....... ... ....... .... .. ...... ...... .............. .... .... .. ...... .... ...... ...... .. ....... .. ......... .. .. 55 
2.1.3 INTRODUCTION ............... .. ....... .. .......... ....... ....... .............. ... .. ....... ....... ... .. .. .. .... .... ...... ..... ....... ..... . .... .. 57 
2. 1.4 MATERIALS & M ETHODS ........ ......................... .. ... .. ...... .............. .... .... .... .. ........... ......... .. ..... .. .. .... .... . 59 
2. 1.5 R ESULTS ...... .. .......... ... ..... .. .. ... .. ........... ........ ..... .. ...... .... ........ ............ ................ ....... ... ..... ........ .... ..... .. 65 
2 . 1.5 .1 High levels ofTubedown express ion in neuroblastic tumors correlates with advanced 
stages and neuroblastic unfavorable histopathology ...... ..... ... .... ...... ... .. .. .... .. .... .................................... .. 65 
2.1.5 .2 High levels ofTubedown in neuroblastoma tumors correlate with high-risk and low 
survival rate ............... .. ...... .. ........ ..... .. .......................................... .. ... ....... ..... ...... .. .. ............ ..... ..... ..... .. ...... 72 
2.1.5.3 Tubedown is down-regulated in neuroblastoma cells undergoing marked neuronal 
differentiation ..... ... .................. ... .. .. ... ... ..... ............ .......... .. .. .. ........... .. ... ... .... ........... .. ..... ........... .... .. ..... ...... 73 
2 .1 .6 DISCUSSION ........................ .................... .... .... ....... ... .. .. .... ......... ... .... ..... ..... .... .. ..... .. ........ ........ ... .... .... 80 
2. 1.7 A CKNOWLEDG EMENTS .................................... ................................ .. ................ .. .... ... .. ... .................. 84 
v 
3.1 TUBEDOWN IS UP-REGULATED BY MYCN IN NEUROBLASTOMA .................................... 85 
3. 1.1 AUTHORS' CONTRIBUTION ................ ...... .... ... ... ..... ... ....... ........ ........... ..... .. .. ...... ....... ... ... ............. .... 86 
3. 1 .2 ABSTRACT ... ... ............ .. ......... ..... .... ...... ...... ........ ..... ... ..... .... ......... .... .. .. ..... ... ... .. .. .. ............ .... ...... ....... 87 
3. 1.3 BACKGROUND .... ........... ......... ........... .. .......... ...... .. .. ...... ................ .... .... ....... ....... .... ... ....... .... ........... .. 89 
3. 1.4 METHODS ...... .. .......... ....... ...... ...... .. ........... ..... .. ... .. ............. ...... ......... ... .... .... ..... ... ...... ..... ...... .... ......... 92 
3.1.5 RESULTS ..... .............. ..... .. .... ........ .... .. .................. .. ..... ....... .... ..... .. .. ................. ....... ........ ................. ... 97 
3 .1 .5. 1 Tbdn and Ard 1 are co-regulated with MycN in neuroblastoma cells undergo ing marked 
neuronal differentiation .. ......................... ....... .. ...... ..... ...... .. ..... ..... ............ .. .... ..... ... ... .... .... .... .............. ... .. 97 
3.1.5.2 Cond itional MycN over-expression leads to up-regulation ofTbdn and Ard 1 ................. 97 
3. 1.5.3 MycN binds a TBDN promoter region ... .......... ..... ...... ....... ........ ... .. ....... ...... ....... .. ...... .... ..... 99 
3. 1 .6 DISCUSSION ... .. ...... .. .............. ................ .... ..... .... ....... ..... .. .......... .. .................................. ....... ...... .. ... I 08 
3 .1.7 CONCLUSIONS ..... ...... ............... ............ ..... ......... .... ... .. ... ....................... ...... ........ ..... .. ......... ............. I 15 
3. 1.8 LIST OF ABBREVIATIONS .......... ... ..... ...... .. ..... .... .. ...... ... ..... ... .......... .. .... ... ... .... .......... ... ... .... ... ....... ... 11 6 
3. 1.9 ACKNOWLEDGEMENTS .. .. ........... ........... .... ... ... ...... .... .... .. ........ ...... ...... .... ..... ... .. .... ...... ............. ....... I I6 
4.1 SUPPRESSION OF TUBEDOWN EXPRESSION ............................................................................ 11 7 
4.1 . I INTRODUCTION .......... .... ... ............................. .. ................ ... .. .. ... ....... ... .. ...... ................ ............... ..... 117 
4.1.2 MATERIALS AND METHODS ....... ...... ...... .. .... ... .... ..... ......... ..... .... ... ..... .... ... ........ ... ..... ... .......... .. .... .. . 11 7 
4. 1 .3 RESULTS & Dr CUSS ION .......... ... .......... ........ ..... ..... ............ .... ..... ....... .... ...... .............. ... .... .... ... ..... . 120 
5.1 SUMMARY ............................................................................................................................................... 127 
5. 1.1 MARTINET AL., 2007 ....................................... ... .. .... ....... ....... ............. ...................... ... .......... ..... ... 127 
5. 1.2 MARTINET AL., 2009 ........... .. ..... ....... ....... ..... .. ... ............ ........ .... .... .... .............. ... .... .... .. ........ .... ..... 130 
5. 1.3 TBDN, ARD I, MYC, AND CANCER ..... ....... ... ..... ....... ... ... ............. .......... ... ...... ........ .. ......... .......... .... I39 
5. 1.4 PITFALLS & FUTURE DrRECTIONS ....... .. ........ ..... ........ .. .. ... ........ ... .. ................. ......... .. ..... .. ... .. ........ 142 
5.1.5 POTENTIAL TUBEDOWN MECHANISM .. ........... .. .. ...... ........... ... ..... ............ ..... .. ........................ .. ...... I46 
6.1 REFERENCES ................ .... ..................................................................................................................... 149 
V I 
Figures 
1-1. Mechanisms leading to pediatric and adult malignancies 2 
1-2. Potential neuroblastic sites 6 
1-3. Model of MycN interactions 27 
1-4. Schematic of Homer-Wright rosettes 32 
1-5. Brief outline of the pathological prognostic categorization ofNTs 38 
1-6. Tubedown-1 and Tubedown-1 00 domains 46 
2-1. Western blot analysis of Tubedown-1 expression in cell lines and 66 
primary neuroblastic tumors 
2-2. Immunohistochemistry analysis of Tubedown expression in 66 
neuroblastic tumors and normal tissues 
2-3. Quantitative analysis of Tubedown expression in neuroblastic 70 
tumors 
2-4. Morphological differentiation of neuroblastoma cells upon retinoic 75 
acid treatment 
2-5. Cell growth of neuroblastoma cells upon retinoic acid-induced 77 
differentiation 
2-6. Expression dynamics ofTubedown, intermediate filaments, c-Myb 79 
and MYCN in neuroblastoma cells upon retinoic acid-induced 
differentiation 
3-1. Tbdn co-regulation with MycN/ Ard 1 during cell differentiation 98 
3-2. MycN over-expression induces Tbdn and Ard 1 expression 102 
3-3. The nucleotide sequence of TBDN promoter region contains a 105 
canonical E-box motif 
3-4. MycN binds to the TBDN promoter 107 
4-1. 'Tet-on' inducible antisense Tbdn system 122 
4-2. Doxycycline effects on antisense Tbdn clones 124 
Vll 
4-3. Nucleofection ofLA-N-5 cells 126 
5-l. Tbdn, Ard1 , and MycN pathway interaction 134 
5-2. Possible mechanism of NatA acetylating Beta-Catenin 137 




~1-1. Neuroblastoma risk groups 
IX 
Abbreviations 
ALK = Anaplastic lymphoma kinase 
A TRA = All-trans retinoic acid 
BDNF = Brain-derived neurotrophic factor 
bHLH = Basic helix-loop-helix 
BMP = Bone morphogenetic protein 
ChiP = Chromatin Immunoprecipitation 
CRABP-11 = Cellular retinoic acid binding protein II 
CT = Computed tomography 
DM = Double-minutes 
GFP = Green Fluorescent Protein 
HASH-1 = Human achaete-scute homologue- I 
HSR = Homogeneously staining regions 
INPC = International Neuroblastoma Pathology Classification 
INSS = International Neuroblastoma Staging System 
IRES = Internal Ribosome Entry Site 
NMDA = N-methyl-D-aspartate 
mARDI = Mouse arrest defective 1 protein 
MASH-1 = Mammalian achaete-scute homologue- I 
MAX = Myc-associated factor x 
MCM 2- 7 = Mini-chromosomal maintenance proteins 2 - 7 
X 
MIBG = Meta-iodo-benzyl guanidine 
MKI = Mitosis-karyorrhexis index 
mNA Tl = Mouse N-acetyltransferase 1 protein 
MRI = Magnetic resonance imaging 
MRPl = Multi-drug resistance-associated protein 
MYCC (c-myc) = cellular myc oncogene 
MYCL (L-myc) = Lung carcinoma derived myc oncogene 
MYCN (N-myc) = Neuroblastoma derived myc oncogene 
MYCV (v-myc) = v-myc myelocytomatosis viral related oncogene (avian) 
NAG = Neuroblastoma-amplified gene 
NB = Neuroblastoma 
NGF = Nerve growth factor 
NT-3 = Neurotrophin-3 
NT -4/5 = Neurotrophin-4/5 
NTs = Neuroblastic tumors 
SBRCT - Small blue round cell tumors 
Tbdn- Tubedown 
Tet2 (SHEPTet2)- Empty vector 
Tet2N (SHEPTet2/Nmyc)- MYCN-inducible SHEP cell line 
UTR - untranslated region 
WNT- Wq (wingless) + INT 
Xl 
1.1 Cancer 
Cancer is a multi-stage process arising from many genetic alterations (Hanahan and 
Weinberg, 2000). Cancer is the result of cumulative mutations, affecting two types of 
genes, oncogenes (stimulate growth), and tumor suppressor genes (inhibit growth). The 
activation of oncogenes or the deactivation of tumor suppressor genes will result in 
tumorigenesis, or the formation of cancer (Gibbs, 2003). The transformation of a normal 
cell into a malignant cell usually results in sporadic or induced cancers (Hanahan and 
Weinberg, 2000). Many factors contribute to tumorigenesis which include physical 
carcinogens (UV radiation, ionizing radiation), chemical carcinogens (nickel, cadmium, 
arsenic) or biological carcinogens (Human papilloma virus B, Helicobacter pylori) 
(Schulz, 2007). 
The majority of adult cancers result from an accumulation of mutations over many years 
(Pahlman et a!., 2004 ). In contrast, pediatric cancers appear earlier. Therefore, it is 
dubious that pediatric malignancies occur from just an accumulation of mutations. 
Pediatric malignancies occur from developmental abnormalities during the normal 
differentiation process (Figure l-1 ; Maris and Denny, 2002; Pahlman eta!., 2004). These 
developmental abnormalities are the result of both sporadic and familial cancers. In 
particular, many pediatric cancers are thought to involve Knudson' s two-mutation 
hypothesis, which states the first mutation is inherited while the second is acquired 
1 











Figure 1-1. Mechanisms leading to pediatric and adult malignancies. 
In children, committed stem cells undergo normal development, resulting in terminally 
differentiated cells. However, during normal growth and differentiation, a 
developmental blockage (represented by 'X') occurs resulting in the formation of 
pediatric malignancies. Conversely, in adults, mature tissues maintains normal 
homeostasis resulting in normal organ function. However, during normal homeostasis, 
cumulative mutations due to genetic mutations and/or environmental exposures (denoted 
by a double line) will result in adult malignancies. 
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somatically (Knudson, 1971 ; Knudson and Strong, 1972). Although there is an obvious 
difference between adult and pediatric cancers, they still share many similar w1derlying 
properties. Six key hallmark features result in malignant growth. They include self-
sufficiency in growth capabilities, unresponsive to antigrowth signals, circumvention of 
apoptotic signals, unlimited replicative potential, sustained angiogenesis and tissue 
invasion and metastasis (Hanahan and Weinberg, 2000; Abbott et al., 2006). 
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1.2 Neuroblastic Tumors 
Neuroblastic tumors (NTs) are the most common extra-cranial tumors occurring in 
children (Mora and Gerald, 2004). NTs are composed of a combination of components 
including undifferentiated neuroblasts, neuropil, differentiating neuroblasts, ganglion 
cells, neuritic processes, Schwann cells, and fibrous tissue (Joshi, 2000). NTs are far 
from a uniform disease as they have varying levels of immature and mature cells. These 
immature neural crest cells are referred to as neuroblasts whereas the mature 
differentiated forms are referred to as ganglion and Schwann cells (Lonergan et al., 
2002). NTs were classified into four groups (ganglioneuroma; ganglioneuroblastoma, 
intermixed; ganglioneuroblastoma, nodular; neuroblastoma), which vary according to 
their range of differentiation (Shimada et al. , 1999a). Ganglioneuromas are (Schwannian 
stroma dominant) benign tumors composed of mature ganglion and Schwann cells. The 
mature ganglion cells are embedded in the stroma which contain the Schwann cell 
sheaths encompassing neural elements (Shimada et al., 1984). Ganglioneuroblastoma -
intermixed (Schwannian stroma-rich) are considered benign tumors composed mainly of 
ganglion cells with the presence of microscopic neuroblast cells which are present at 
different stages of differentiation. Conversely, ganglioneuroblastoma - nodular 
(composite Schwannian stroma-rich/stroma-dominant and stroma-poor) contains more 
aggressive and malignant composite of neuroblast clones. Neuroblastomas are 
(Schwrumian stroma-poor) tumors consist mainly of immature, undifferentiated cells 
(Shimada et al. , 1999a). 
4 
1.3 Neuroblastoma 
In 1864, Rudolf Virchow originally described neuroblastoma as a glioma (Joyner and 
Lopushnyan, 2007). However, it was not until 1910 that James Homer Wright officially 
introduced the term 'neuroblastoma'. Wright demonstrated that neuroblastoma 
originated from embryonic neuroblasts or neural crest cells (Joyner and Lopushnyan, 
2007). Neuroblastoma is a disease of the trunk region of the neural crest which gives rise 
to the sympatheticoadrenallinkage of neural crest cells (Dyer, 2004; Maris et al. , 2007). 
Due to the high migratory nature of the neural crest cells they can arise anywhere along 
the sympathetic nervous system during embryogenesis (Figure 1-2; Maris, 2005 ; 
Howman-Giles et al., 2007; Bowen and Chung, 2009). The sympathetic nervous system 
is responsible for involuntary actions of the body, such as increasing heart rate, 
decreasing urine secretion, and dilating the pupils of the eye (Sherwood, 1997). During 
normal development, neural crest stem cells migrate to many areas within the embryo. 
The Trunk region of the neural crest stem cells give rise to sympathetic tissues which 
include sympathetic neurons, sympathetic ganglia, Schwann cells and adrenomedullary 
cells (Dyer, 2004; Mora and Gerald, 2004). However, a developmental blockage of the 
neural crest stem cells will disturb the normal proliferation and migration of these cells, 
resulting in pediatric embryonal malignancies. 
Although greater than fifty percent of neuroblastomas occur in the adrenal medulla, other 
primary sites of neuroblastoma formation include the chest, neck and pelvis (Maris et al., 
2007). Prior to a neuroblastoma diagnosis, fifty percent of the cases will present 
5 
Figure 1-2. Potential neuroblastic sites. 
Neuroblastic tumors can arise anywhere along the sympathetic nervous system. The 
chains of sympathetic ganglia (red) run along the spinal chord (light gray) and the 
occurrence of NTs can invade the spine including the spinal nerves. The adrenal glands 
(yellow) site on top of each kidney (brown) and are the source of catecholamines, 
epinephrine and norepinephrine. 
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metastasis to areas such as the bone, bone marrow, liver and/or lungs (Castel et al., 2007; 
Howman-Giles et al. , 2007; Ishola and Chung, 2007). Neuroblastoma is one of the most 
complex yet intriguing diseases for scientists and clinicians. Half of the patients 
diagnosed with neuroblastoma, die from the disease (Pahlman et al., 2004). 
Paradoxically, neuroblastoma also has one of the highest rates of spontaneous regression 
(Pritchard and Hickman, 1994; Castel et al., 2007). 
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1.3. 1 Spontaneous Regression & Apoptosis 
In the mid 1980s, a mass screening detection program was initiated in Japan to improve 
the discovery of neuroblastoma (Sawada et al., 1984). Japan began screening six-month 
old infants for catecholamine metabolites (produced by neuroblastoma) found in the 
urine. Subsequently, similar efforts were taken by Canada and Germany to determine the 
practicality and effectiveness of these screening programs (Schilling et al. , 1994; Woods 
et al., 1996). The screening program in Japan was terminated in 2004 after studies from 
Canada and Germany revealed that there was no reduction in the mortality rate (Tsubono 
and Hisamichi, 2004). In fact, there was an increase in the incidence of neuroblastoma 
since the induction of the mass screening program. The program proved unsuccessful 
due to an over-detection of the biologically favorable type of neuroblastomas, ultimately 
leading to unnecessary treatments. The treatments were deemed unnecessary, as this 
class of tumors would have likely undergone spontaneous regression before any clinical 
signs were present (Brodeur, 2003; van Noesel and Versteeg, 2004). In addition to 
adding a greater understanding about spontaneous regression, other important 
observations came from the screening program. The idea that neuroblastoma may not 
necessarily be derived from a common precursor and in fact may arise as separate entities 
(favorable and unfavorable). There is now a greater awareness that spontaneous 
regression occurs in neuroblastomas, and at a higher rate than any other human tumor. 
However, the reason for such a high rate of spontaneous regression is still unclear. 
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Neuroblastoma has the highest rate of spontaneous regression (1 0 to 100 times) of any 
cancer (D'Angio et al., 1971; Pritchard and Hickman, 1994; Castel et al., 2007). Two 
hypotheses have been suggested for this occurrence, including immunological attack on 
the tumor (Hellstrom et al. , 1968) and spontaneous maturation (Rangecroft et al. , 1978). 
Hellstrom and colleagues demonstrated that there was an inhibition of neuroblastoma cell 
growth in vitro using lymphocytes from children with neuroblastoma. In addition, using 
lymphocytes from a mother who had given birth to a child with neuroblastoma also 
inhibited neuroblastoma growth in vitro (Hellstrom et al., 1968). The problem with the 
first theory is the lack of immunological evidence for immune surveillance (or the lack of 
constant monitoring by the immune system) against the development of neuroblastomas 
(Pritchard and Hickman, 1994; Ochsenbein et al., 1999). In addition, neuroblastomas are 
not highly immunogenic, meaning that they express low levels of surface antigens that 
would be required for proper immune surveillance (Brodeur, 2003). Other reasons that 
spontaneous regression is not supported by the immunological theories is that children do 
not develop neuroblastoma from inherited immune deficiencies or after receiving 
immunosuppressant therapy (Pritchard and Hickman, 1994). 
The second theory regarding spontaneous maturation also seemed implausible. 
Rangecroft et al. reported a case in which a stage 4S neuroblastoma spontaneously 
matured with minimal treatment (Rangecroft et al. , 1978). Usually during spontaneous 
regression of a stage 4S neuroblastoma, the tumor disappears completely (the liver and 
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bone marrow biopsy specimens are tumor-free). In addition, there should be no traces of 
a treated tumor ever existing. In other words, no ganglion (or differentiated) cells would 
be left behind. However, in this case spontaneous maturation to ganglioneuroma had 
occurred leaving residual mature ganglion cells (Pritchard and Hickman, 1994). 
Pritchard and Hickman suggested that the most likely explanation for the spontaneous 
regression observed in neuroblastoma is a delay in the time-switch for apoptosis during 
normal development (Pritchard and Hickman, 1994) and after a period, the apoptotic 
pathway becomes activated. Massive cell death of sympathetic neurons occur during the 
perinatal period (Oppenheim, 1991; Nakagawara, 2005). The same controlled cell death 
mechanism appears to occur in neuroblastoma, resulting in the regression of the tumor. 
Oue and colleagues used in situ detection of DNA fragmentation and Bcl-2 expression to 
demonstrate a relationship between apoptosis and spontaneous regression in 
neuroblastoma (Oue et al. , 1996). High Bcl-2 expression has been shown to block 
apoptosis in the advanced stages of neuroblastoma (Oue et al., 1996). Previously, Bcl-2 
expression was reported to correlate with poor prognosis, unfavorable histology, and 
MYCN amplification (Castle et al. , 1993). They suggested that Bcl-2 might have a role in 
neuroblastoma progression. However, Bcl-2 levels were decreased in children less than 
one year of age (Oue et al. , 1996). The reports regarding the prognostic significance of 
Bcl-2 levels in primary tumors are varied. Therefore, the role that Bcl-2 plays in 
spontaneous regression still remains elusive. Moreover, Bcl-2 may have a more 
significant role in acquired resistance to chemotherapy (Maris and Matthay, 1999). Over 
eighty percent of neuroblastoma specimens analyzed post-chemotherapy treatment 
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expressed Bcl-2 (Castle et al., 1993). Dole et al. demonstrated that over-expression of 
Bcl-2 in neuroblastoma clones inhibited apoptosis, even in the presence of chemotherapy 
treatment (Dole et al., 1994). Their results suggested that Bcl-2 promoted tumor 
resistance to chemotherapy agents. 
Caspase-8 is an integral part ofthe death receptor (extrinsic) apoptotic pathway (van 
Noesel and Versteeg, 2004). In general, many human cancers, including neuroblastoma, 
evade apoptosis through inactivation of Caspase-8. The function of Caspase-8 can be 
impaired due to epigenetic mechanisms or genetic deletions (Fulda, 2009). However, 
Eggert and colleagues demonstrated through demethylation experiments, the restoration 
of Caspase-8 expression using neuroblastoma cell lines. Their results suggested that the 
mechanism leading to the loss of Caspase-8 expression was likely due to DNA 
methylation as opposed to deletion of CASP ASE-8 (Eggert et al., 2000). In advanced 
neuroblastomas, the inactivation of CASPASE-8 occurs via promoter hypermethylation. 
This represents a defective hallmark for apoptosis, suggesting that Caspase-8 may serve 
as a tumor suppressor (Teitz et al., 2000; Teitz et al., 2001). Unfortunately, the 
regulatory region of the CASP ASE-8 promoter does not contain classical CpG islands or 
even have promoter activity as was displayed using neuroblastoma cell line and primary 
tumor samples (Fulda, 2009). Nevertheless, reports show that demethylation (using 5-
Aza-Cytidine) restores Caspase-8 expression (Eggert et al. , 2000; Banelli et al., 2002; 
Fulda, 2009). 
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The loss of Caspase-8 expression has been reported to be as low as 25-35%, and as high 
as 75% in neuroblastomas (van Noesel and Versteeg, 2004; Fulda eta!., 2006). In 
addition, there is much controversy between Caspase-8 expression and MYCN 
amplification. Some studies suggest that the loss of Caspase-8 strongly associate with 
MYCN amplification (Teitz et al., 2000), whereas other reports show no such correlation 
(Fulda et al., 2006). In addition, loss of Caspase-8 did not associate with the 
aggressiveness, prognosis or staging of neuroblastoma (Fulda et al., 2006). 
Similar to Caspase-8, Survivin is also involved in the apoptotic pathway. However, 
SURVJVJN is an anti-apoptotic gene that is located on the long arm of chromosome 17. 
The Survivin protein is a member of the inhibitor of apoptosis, and is a negative regulator 
of Caspase-9 (van Noesel and Versteeg, 2004). Over-expression of Survivin is associated 
with high-risk neuroblastomas (Adida et al., 1998; Nakagawara, 2005). 
As mentioned, neuroblastoma can also undergo spontaneous maturation (Castel and 
Grau, 2006). In the late 1920s, Cushing and Wolbach described that malignant 
neuroblastoma, consisting of immature neuroblastic cells, underwent spontaneous 
maturation into benign ganglioneuroma, consisting of mature ganglion cells (Cushing and 
Wolbach, 1927; Brodeur, 2003). A limited number of cases have been reported involving 
the complete maturation and regression of neuroblastoma (Stage IVS) without surgery or 
chemotherapy (Rangecroft et al. , 1978; Haas et al., 1988). Conversely, other studies have 
rep01ted that even minimal treatment have resulted in spontaneous regression of 
neuroblastoma (Evans et al. , 1976; Howman-Giles et al., 2007). 
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1.3.2 Epidemiology 
Neuroblastoma is one ofthe most common extra-cranial solid tumors occurring in 
children. During the first year of life, neuroblastoma accounts for fifty percent of all 
solid tumors (Castel eta!., 2007). Only accidents precede neuroblastoma as the most 
common cause of death among children (Castel et al., 2007). Ninety percent of patients 
are diagnosed during the first 5 years of life while the median age for diagnosis is 
approximately 18 months (Brodeur, 2003; Castel et al., 2007; Howman-Giles eta!. , 
2007). In Canada, there are 65 new cases diagnosed each year compared to 700 new 
cases reported in the United States. The prevalence of neuroblastoma is about 1 in 7000 
live births and it accounts for approximately 15 percent of all childhood cancers 
(Brodeur, 2003 ; Maris et al., 2007). A more staggering statistic is that fifty percent of all 
children diagnosed with neuroblastoma will die from the disease (Pahlman et al. , 2004). 
Several epidemiologic studies have focused on the many potential risk factors for 
neuroblastoma. There are theories such as maternal use of illicit or recreational drugs 
such as marijuana (Bluhm et al. , 2006) and maternal use of hair dye (McCall et al. , 2005) 
before or during pregnancy, both increasing the risk for neuroblastoma. Conversely, 
activities such as maternal vitamin usage (Olshan et al., 2002) and breast-feeding 
(Daniels et al., 2002) suggested a decrease in the risk for neuroblastoma. However, 
proving the aforementioned theories will require further investigation. 
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A retrospective population-based cross-sectional study was completed at the Hospital for 
Sick Children in Toronto, Canada that examined pre-folic acid fortification (from January 
1985 to December 1997) and post-folic acid fortification (from January 1998 to October 
2000) food (French et al. , 2003). French et al. suggested that the recent decline in 
neuroblastoma (from 1.57 cases per 10 000 births to 0.67 cases per 10 000 births) was 
attributed to folic acid fortified food (French et al. , 2003). The decline observed in this 
study may be due to the relatively short follow-up time (25 months) for children 
conceived after folic acid fortification. In addition, Barone & Bunin estimated that 3 7% 
of the children would still get neuroblastoma even after folic acid fortification (Barone 
and Bunin, 2004). Interestingly, the incident rate comparing children conceived before 
and after fortification is 40%, very close to the predicative value. Although folic acid 
supplementation appear to have little effect on neuroblastoma prevention, more studies 
including longer follow-up times would be required to fully develop this relationship. 
1.3.3 Genetic Predisposition 
Neuroblastoma is predominantly a sporadic cancer resulting from a somatic cell 
mutation, which is restricted to the affected individual (Schwab, 1997). Dodge and 
Brenner first clinically described familial neuroblastoma in 1945 (Maris and Brodeur, 
2005). Familial neuroblastoma occurs in one to two percent of neuroblastoma cases and 
results from a germ line mutation. Germ line mutations are not restricted to the affected 
individuals but passed to the offspring (Schwab, 1997; Maris and Matthay, 1999; Maris 
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et al., 2007). Like familial retinoblastomas, familial neuroblastomas is a multi-stage 
process consistent with Knudson's two-mutation hypothesis (Knudson, 1971 ; Knudson 
and Strong, 1972; Schwab, 1997; Maris et al., 2007). One ofthe hallmarks offamilial 
neuroblastoma is multiple primary tumor sites (Kushner et al., 1986), which again is in 
accordance with Knudson's two-mutation model (Knudson and Strong, 1972). 
Hereditary neuroblastoma is an autosomal dominant disease with reduced penetrance 
(Brodeur, 2003; Maris et al. , 2007). In 2000, a hereditary neuroblastoma predisposition 
locus (HNBJ) was mapped to the short arm of chromosome 16, 16pl2-13 (Weiss et al., 
2000; Maris et al., 2002). However, no causal gene for hereditary neuroblastoma was 
found to be associated with the 16p12-13 region (Maris eta!., 2007). In 2003, Arnie! et 
al. reported neuroblastoma cases containing mutations of the P HOX2B gene (Arnie! eta!. 
2003). However, no such evidence for a hereditary linkage to the short arm of 
chromosome 4 was found (Maris eta!., 2002; Maris and Brodeur, 2005). In 2004, 
Trochet and colleagues reported that mutations to the PHOX2B gene had a hereditary 
predisposition to neuroblastoma (Mosse et al., 2004; Trochet et al. , 2004). Recently, 
Mosse and colleagues identified the anaplastic lymphoma kinase (ALK) gene as a key 
factor in familial neuroblastoma patients. Heritable mutations to the ALK gene are found 
in a subset of neuroblastoma cases (Mosse et al. , 2008). In 2000, the presence of ALK 
expression in neuroblastoma was first described (Lamant et al., 2000). However, ALK 
expression was not limited to neuroblastoma but was also present in cancers such as 
breast and rhabdomyosarcoma (Chiarle et al., 2008). 
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1.3.4 Neural Crest Development 
Wnt [Wg (Wingless) and Int] signaling is one of the earliest events in the transition of 
ectodermal cells into neural crest cells. Bone morphogenetic proteins (BMPs) help 
trigger and maintain the differentiation process of neural crest cells (Pahlman et al., 
2004). Differentiation into sympathetic neurons involves many factors including basic 
helix-loop-helix (bHLH), homeobox genes, and tumor suppressor genes (Nakagawara, 
2005). 
In 1991 , Lo et a!. demonstrated that the bHLH factor mammalian achaete-scute 
homologue- I (MASH-1 ; HASH-1 in humans) had transient expression in neural crest cells 
(Lo et al., 1991 ). MASH-1 null mice were used to prevent the generation of sympathetic 
neurons (Guillemot et al., 1993). In addition, Mash-1 (or Hash-1) is essential for the 
proper formation of the sympathetic nervous system (Axelson, 2004). Meanwhile, Hash-
1 is present in primary neuroblastomas and neuroblastoma cells indicating the derivation 
of neuroblastoma from immature neural crest cells of the sympathetic nervous system 
(Axelson, 2004; Pahlman eta!. , 2004). 
1.3.5 Biological Pathways 
Neurotrophins are a family of proteins that bind to a receptor on a nerve cell (Brodeur, 
2003). The neurotrophin family consists of four main ligands including nerve growth 
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factor (NGF), brain-derived neurotrophic factor (BDNF), new-otrophin-3 (NT-3), and 
neurotrophin-4/5 (NT-4/5), each binding to specific receptors. NGF binds preferentially 
to Trk A, BDNF to TrkB, NT-3 to TrkC and NT-4/5 prefers TrkB but also weakly binds 
to TrkA (van Noesel and Versteeg, 2004; Nakagawara, 2005). The p75 new-otrophin 
receptor (p75NTR) is a member of the tumor necrosis factor receptor that can bind all four 
neurotrophins but at a lower affinity than the Trks. The neurotrophin receptors and their 
corresponding ligands are important regulators for neuronal cell survival, growth, and 
differentiation (Maris et al. , 2007). 
High expression ofTrkA receptor is found in mature sympathetic ganglia (van Noesel 
and Versteeg, 2004), as well as in neuroblastoma tumors with favorable prognosis 
(Nakagawara et al. , 1993). Moreover, high expression ofTrkA receptor is found in 
young neuroblastoma patients with a low stage tumor that is MYCN non-amplified (van 
Noesel and Versteeg, 2004). Neuroblastoma cells expressing TrkA can undergo 
differentiation or apoptosis depending on the microenvironment of the tumors (Brodeur 
et al. , 2009). In the presence ofNGF, new-oblastoma cells expressing TrkA will undergo 
differentiation. However, in the absence ofNGF, neuroblastoma cells expressing TrkA 
will undergo apoptosis (Nakagawara et al. , 1993). Conversely, low TrkA receptor 
expression is found in neuroblastoma tumors associated with MYCN amplification and 
poor outcome (Kogner et al., 1993; Nakagawara et al., 1993; Brodeur, 2003). Similar to 
TrkA, TrkC is expressed in the lower-stage tumors and is absence in MYCN-amplified 
new-oblastomas (Ryden et al. , 1996; Yamashiro et al. , 1996; van Noesel and Versteeg, 
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2004). Also, p75NTR expression is, in general, associated with a favorable outcome for 
neuroblastoma patients (Brodeur, 2003). Conversely, TrkB expression is associated with 
tmfavorable neuroblastomas (Maris et al., 2007). In particular, the fu ll-length TrkB and 
corresponding BDNF ligand are associated with MYCN-amplified high-risk 
neuroblastomas (Nakagawara et al., 1994). MYCN amplification contributes to the 
aggressiveness of neuroblastomas (Seeger et al., 1985). 
1.3.6 Myc Family 
The v-MYC oncogene was originally identified as a transforming determinant of avian 
acute leukemia virus MC29 (Bister et al. , 1977; Duesberg et al. , 1977; Vita and 
Henriksson, 2006). c-MYC (also referred to as MYCC or MYC), the cellular homologue 
ofv-MYC, was first described in 1982 (Vennstrom et al. , 1982). In 1983, the MYCN gene 
was reported to share homology with the MYC cellular oncogene (Kohl et al. , 1983; 
Schwab et al. , 1983). In 1985, L-MYC (MYCL) was first reported by Nau and colleagues 
(Nau et al. , 1985). MYC, MYCL, and MYCN are localized to 8q24, lp32 and 2p23-24, 
respectively (Schwab, 2004). The MYCL and MYCN genes are 35% and 38% identical to 
the amino acid sequence of MYC (Ryan and Birnie, 1996). 
The MYC genes encode transcription factors that are involved in a wide range of 
processes including but not limited to cell proliferation, differentiation and apoptosis 
(Vita and Henriksson, 2006). The expression pattern of the transcription factors is 
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distinct throughout embryogenesis (Nesbit et al., 1999). During development, there is a 
high expression pattern noted by Myc, MyeL, and MycN, which upon maturation their 
expression is down-regulated (Hatton et al., 1996). Myc is expressed mainly in rapidly 
proliferating cells whereas MyeL is primarily expressed in the developing kidney, lung, 
brain, and neural tube. MycN is highly expressed in the pre-B cells, kidney, forebrain, 
hindbrain, and intestine (Nesbit et al., 1999). 
Knockout models of the MYC family loci helped to further differentiate the functions of 
the genes (Nesbit et al., 1999). Homozygous null MYC mice are embryonic lethal on or 
after I 0.5E with abnormalities including reduced embryo size, dilated pericardia, 
enlarged hearts, delay or failure in forming the neural tube and in the axial rotation of the 
embryo (Davis et al. , 1993). Homozygous null knockout of MYCN survived past 11.5E 
but reached embryonic lethality at 12.5E. The major challenge with these mice were the 
developmental defects in tissues expressing MYCN. Contradictory to the outcomes for 
both MYC and MYCN, Hatton and colleagues reported MYCL knockout mice to be viable. 
The mice lacking MYCL did not reveal any phenotype even though the expression of 
MYCL was abundant during the development of the central nervous system (Hatton et al. , 
1996). 
The MYC and MYCN genes are highly conserved and share many common features. 
Both genes are involved in oncogenesis and the knockout of either gene results in 
embryonic lethality. They encode transcription factors that dimerize with Max, a 
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ubiquitously expressed bHLH family member. Both Myc/Max and MycN/Max can bind 
the same DNA target sequence, CACGTG (Lu eta!., 2003). In addition, an in vivo study 
demonstrated that MYC and MYCN share similar targets. The endogenous Myc coding 
sequence was functionally replaced with a MycN coding sequence, which resulted in 
viable mice (Malynn eta!., 2000). Interestingly, the MYC promoter was used to drive the 
synthesis of the MYCN transcript instead of the MYC transcript. Nevertheless, the 
homozygous mice for the MYCN mutation were able to survive into adulthood and were 
capable of reproducing (Malynn et al. , 2000). 
The Myc fan1ily of proto-oncogene such as MYC, MYCL and MYCN are widely known to 
be deregulated in many human cancers (Nesbit eta!., 1999). Their deregulation can 
range from gene amplification to over-expression, giving this family strong oncogenic 
potential (Mukherjee et a!. , 1992; Vita and Henriksson, 2006). Deregulation is often 
associated with aggressive and poorly differentiated tumors, which can assume various 
forms including gene amplification, over-expression, or translocation (Vita and 
Henriksson, 2006). Myc over-expression and MYC amplification have been linked to 
solid tumors such as breast and colon whereas hematological malignancies such as 
Burkitt's lymphoma possess over-expression and translocation (Vita and Henriksson, 
2006). MYCL amplification is primarily associated with small-cell lung carcinoma 
whereas ovarian cancers contain both over-expression and gene amplification (Vita and 
Henriksson, 2006). MYCN amplification has been mainly associated with neuroblastoma 
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(Vasudevan eta!., 2005) and is considered to be one of the most consistent genetic 
aberrations associated with neuroblastoma (Maris et al., 2007). 
The MYCN gene is located on the short arm of chromosome 2. However, during gene 
amplification, MYCN can be found as double-minutes (DMs) or homogeneously staining 
regions (HSRs) (Schwab et al., 1984). DMs are extrachromosomal pieces containing 
multiple copies of the same gene whereas HSRs are uniformly stained regions of a 
chromosome, which contain multiple copies of the same gene. Amplification of the 
MYCN gene refers to an increase in gene copy-number of 50 - 400 copies per cell (Maris 
and Matthay, 1999; Schwab, 2004 ). As previously mentioned, MYCN was originally 
characterized as a MYC related gene (Kohl et al., 1983; Schwab et al., 1983). The amino 
acid sequences that encode exons 2 and 3 are 27 and 39 percent identical, respectively 
(Stanton eta!., 1986). 
MYCN gene amplification, found frequently in neuroblastoma, was initially thought to be 
specific only for neuroblastoma (Schwab, 2004). MYCN gene amplification is also 
present in other neuronal origin tumors such as glioblastoma, small cell lung cancer, 
peripheral neuroectodermal tumors, and retinoblastoma. However, the incidence rate in 
the later tumors are much lower than in neuroblastoma (Schwab, 2004; Vita and 
Henriksson, 2006). 
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MYCN amplified neuroblastoma tumors usually result in over-expression of the MycN 
protein (Tang eta!. , 2006). However, neuroblastoma tumors that lack MYCN 
amplification can still express the MYCN oncogene (Nisen eta!., 1988; Seeger et a!. , 
1988; Slave et al., 1990). The controversy arises regarding the clinical significance with 
respect to MycN expression in MYCN non-amplified tumors. 
Chan and colleagues demonstrated that MycN expression could be utilized as a predicator 
for neuroblastoma prognosis (Chan eta!., 1997). Immunohistochemistry was performed 
on 57 non-localized neuroblastoma specimens. Chan and colleagues used two 
monoclonal antibodies specific for the MycN protein. Seeger and colleagues performed 
immunohistochemistry on 126 neuroblastoma specimens with a polyclonal MycN 
antibody. Their results showed that MYCN amplified and MYCN non-an1plified twnors 
expressed significant amounts of the My eN protein. Their results suggested that the 
MycN protein has no prognostic significance (Seeger et a!. , 1988). Therefore, aggressive 
tumors without MYCN amplification but high protein expression may rely on an 
alternative mechanism to transform neuroblastoma cells. Bordow and colleagues showed 
that a high level of My eN expression was predictive for poor outcome in older children 
with neuroblastoma. However, such a prognostic value was not present in infants with 
neuroblastoma (Bordow et al. , 1998). Cohn et al. reported that MycN expression does 
not have prognostic significance with respect to adverse outcome in patients with 
advanced-stage MYCN non-amplified neuroblastomas (Cohn et al. , 2000). Irrespective of 
MYCN amplification status of the neuroblastoma tumor, the probability of death was 
22 
l 
unaffected as long as the tumors did not over-express MycN. Patients with MYCN non-
amplified tumors that over-expressed MycN showed a low survival. Moreover, MYCN 
amplification was not related to clinical outcome in patients that did not over-express 
MycN (Alaminos et al. , 2005). 
As mentioned, some authors find a correlation between MycN over-expression and 
clinical outcome (Bordow et al., 1998; Lasorella et al. , 2002; Vandesompele et al., 2003), 
whereas others fail to find any correlation (Cohn et al. , 2000). The consensus with all of 
the above-mentioned studies (Bordow et al., 1998; Brodeur, 2003) is that in order to 
rectify the MycN controversy a large prospective study using standardized methods of 
treatment and detection will be required. 
In general, having MYCN amplification I MycN over-expression is not favorable for the 
patient. However, could having MYCN amplification I MycN over-expression make 
neuroblastoma easier to treat? MYCN amplification I MycN over-expression may 
actually serve as a weakness for neuroblastoma during chemotherapy treatments (lshola 
and Chung, 2007). MycN over-expressing tumors respond more favorably to 
chemotherapy treatment than tumors lacking MycN expression. Paffhausen and 
colleagues used a well-established MYCN-inducible cell line model (SHEPIMycN) to 
demonstrate that upon exposure to anti-tumor agents, MYCN induced cells underwent 
apoptosis (Paffhausen et al. , 2007). These results suggest that MycN expression makes 
neuroblastoma cells more susceptible to chemotherapy treatments. 
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Brodeur and colleagues demonstrated a correlation between MYCN gene amplification 
and advanced neuroblastoma disease (Brodeur et al., 1984). MYCN gene amplification 
occurs in one third of advanced neuroblastoma cases, and rarely occurs in low stage cases 
indicating that amplification happens later in the tumorigenesis process (Kohl et al., 
1983; Brodeur et al., 1984). MYCN gene amplification was reported to be associated 
with rapid disease and poor outcome (Seeger et al. , 1985). Weiss and colleagues 
performed a hallmark experiment regarding the role of MYCN in neuroblastoma 
development (Weiss et al. , 1997). In particular, Weiss et al. demonstrated that targeted 
over-expressed of MYCN in a mouse model can contribute to the transformation of 
neuroblasts (Weiss et al. , 1997). The transgenic mice were under the control of a tyrosine 
hydroxylase promoter that targeted neuronal tissue. The targeted expression of MYCN 
ultimately led to the development of neuroblastoma (Weiss et al. , 1997). Weiss and 
colleagues demonstrated that their murine model mirrored the human form of 
neuroblastoma. Specifically, the location of the tumors, the dosage of the MYCN gene 
affecting tumorigenesis, the histological characteristics, the positive staining for 
synaptophysin and neuron-specific enolase, and the syntenic gains and losses of 
chromosomes (Weiss et al. , 1997). 
Knocking down or silencing MycN expression inhibits neuroblastoma cell growth, as 
well as induces apoptosis and differentiation (Negroni et al., 1991; Whitesell et al. , 1991 ; 
Nara et al. , 2007). Particularly, inhibition ofMycN expression with antisense 
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oligodeoxynucleotides resulted in a decrease in the proliferation rate of the LA-N-5 
neuroblastoma cells in vitro (Negroni et al., 1991 ). 
RA (retinoic acid) treatment of neuroblastoma cells leads to a decrease in MycN 
expression prior to undergoing differentiation (Thiele et al., 1985). RA treatment of 
neuroblastoma cells negatively regulates MycN expression and decreases growth while 
inducing differentiation. Constitutive over-expression of MycN in a RA treated 
environment resulted in cellular proliferation (Peverali et al., 1996). Conversely, 
constitutive over-expression of Max in a differentiated environment led to the growth 
arrest and differentiation of neuroblastoma cells. This study suggests that the levels of 
MycN to Max appears to be a critical factor in neuroblastoma growth and differentiation 
(Peverali et al., 1996). 
Members of the Myc family encode nuclear proteins which serve as transcription factors 
(Schwab, 2004). The Myc family of proteins contains a transcriptional activation domain 
in the N-terminus. In the C-terminus there is a transcriptional regulation domain, 
including a basic helix-loop-helix I leucine zipper (bHLHZip) domain (Lu et al., 2003). 
The bHLHZip region is capable of binding other proteins with a bHLHZip domain, as 
well as mediating DNA-binding. To activate transcription the MycN protein must first 
heterodimerize with the Max protein. Max is a ubiquitously expressed nuclear protein 
that also contains a bHLHZip domain (Maris and Matthay, 1999). Max can 
homodimerize to repress transcription or heterodimerize with MycN to activate 
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transcription (Blackwood et al. , 1991 ; Lu et al., 2003). The MycN/Max complex 
recognizes and binds to canonical E-box motifs (CACGTG or CATGTG) with high 
affinity resulting in transcriptional activation of target genes (Vasudevan et al., 2005). In 
addition, Max also heterodimerizes with Mxi 1 or Mad to repress transcription. However, 
with an increase in MycN nuclear protein production usually from genomic amplification 
(Tang et al. , 2006), the MycN/Max dimer complex is favored over the formation of 
Max/Mxi1, Max/Mad or Max/Max (Figure 1-3; Wenzel and Schwab, 1995; Maris and 
Matthay, 1999; Lu et al., 2003). The MycN/Max dimer will target an E-box sequence 
located within the 5' -UTR I promoter region of the MYC-targeted genes. 
For over 20 years, MYCN gene amplification remains prognostically relevant (Cohn and 
Tweddle, 2004) and is the most widely accepted predictive parameter for clinical 
diagnosis of neuroblastoma. Currently, MYCN remains the only clinical relevant 
amplified oncogene in neuroblastoma cells. MYCN gene amplification usually leads to 
high MycN protein and RNA expression in neuroblastoma tumors (Tang et al. , 2006). 
Amplification of the MYCN gene and over-expression of My eN protein is indicative of 
increased tumor growth and tumorigenicity (Seeger et al. , 1985; Weiss eta!., 1997; Cohn 
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The MycN nuclear protein heterodimerize with Max forming a complex that will 
recognize the £-box motif in the promoter region of the target gene and activate 
transcription. However, in the absence of MycN, Max can heterodimerize with Mxil or 
Mad leading to transcriptional repression of the target gene. In addition, Max can also 
homodimerize which will also lead to transcriptional expression. 
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1.3. 7 Chromosomal Aberrations 
In addition to MYCN gene amplification, cytogenetic aberrations are also associated with 
poor outcome in neuroblastoma. Neuroblastoma tumors with chromosome aberrations 
have a near-diploid karyotype, resulting in chromosomal rearrangements and unbalanced 
translocations. These tumors tend to be more aggressive and have a more adverse 
outcome than tumors with mitotic dysfunction. Neuroblastoma tumors with mitotic 
dysfunction are less aggressive and are associated with whole chromosome gains or 
losses (Brodeur, 2003 ; Maris eta!. , 2007). 
Brodeur reported that a deletion in the short arm of chromosome 1 (containing a yet 
unidentified tumor suppressor) is found in patients with advanced stages of 
neuroblastoma (Brodeur, 2003). In addition to the allelic loss of chromosome lp, there is 
a high association with MYCN gene amplification. The majority of neuroblastoma cases 
that have MYCN gene amplification also have the allelic loss of chromosome 1 p. 
However, the reverse is not necessarily true, suggesting that 1 p deletion may occur before 
MYCN gene amplification (Brodeur, 2003). A deletion of chromosome 1p occurs in 25 -
35% of neuroblastomas and correlates with unfavorable outcome (Caron et al. , 1996b; 
Maris et a!. , 2007). In addition, deletion in chromosome 1 p correlates with an1plification 
of the MYCN oncogene. Although the loss of chromosome 1 p may predict disease 
progression, it does not appear to decrease the overall survival of the neuroblastoma 
patients (Maris eta!., 2000; Maris eta!., 2007). 
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Gains in the long arm of chromosome 17 (17q 23-qter) is one of the most common 
genetic abnormalities found in primary neuroblastomas. Caron et al. described the gain 
in 17q as an indicator of poor prognosis (Caron, 1995). Later reports suggested 17q as an 
independent predicator of unfavorable outcome in neuroblastoma patients (Lastowska et 
al., 1997). Ninety percent of high-risk neuroblastoma patients have a gain in 
chromosome 17q (Vasudevan et al., 2005). 
Another common genetic aberration found in 35-45% of neuroblastomas involves 
chromosome 11 . An unbalanced deletion of chromosome 11 usually results in an 
aggressive phenotype. However, this aberration is rarely associated with MYCN gene 
amplification despite being associate with other high-risk factors (Brodeur, 2003; Maris 
et al., 2007). 
1.3.8 Differentiation 
Neuroblastoma arises in the sympathetic nervous system from a defect during normal 
neuro-ectodermal development (Brodeur, 2003; van Noesel and Versteeg, 2004; Maris, 
2005; Vasudevan et al. , 2005). A down-regulation of HASH-1 mRNA expression occurs 
upon induced differentiation of human neuroblastoma cells (Soderholm et al., 1999). 
This down-regulation of HASH-1 was not cell-type specific and was irrespective of the 
differentiate agent used (Axelson, 2004). In addition, Ichimiya et al. used neuroblastoma 
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cells that did not differentiate and did not express HASH-I (Ichimiya et al., 2001 ). These 
studies provide additional evidence for the transformation of neuroblastic cells into more 
mature differentiated cells. Morphological differentiation can be observed in many 
neuroblastoma cells lines (Sidell et al., 1983; Abemayor and Sidell, 1989). In particular, 
the LA-N-5 human neuroblastoma cell line is one of the most well-established models for 
studying differentiation (Sidell et al. , 1983; Hill and Robertson, 1997). Untreated LA-N-
5 cells are small and round with few protruding neurites. However, upon RA-induced 
differentiation, LA-N-5 cells undergo a morphological transformation. The cells produce 
a large number of neurites that form a strong network and the cells tend to clump and 
roundup (Robson and Sidell, 1985). In addition, molecular markers such as 
neurofilan1ent and vimentin confirm the immature form from the well-differentiated form 
(Hill and Robertson, 1997; Pahlman eta!., 2004). 
1.3.9 Histology 
Small blue round cell tumors (SBRCT) include tumors such as Ewing's sarcoma, Wilms' 
tumor, retinoblastoma, and neuroblastoma that have a tendency to arise in children. In 
addition, SBRCT share common histological characteristics upon hematoxylin and eosin 
(H & E) staining (Pisick eta!., 2003). SBRCT are undifferentiated, small round cells 
with large nuclei that stain dark blue upon H & E staining. 
30 
In particular, neuroblasts are uniformly sized cells that appear blue, due to their large 
dark nuclei and scant cytoplasm. Homer-Wright rosettes are a characteristic feature of 
neuroblastoma. However, rosettes may not always be present. Rosettes are formed using 
a circular pattern of neuroblast cells that sunound neuropil, which are neurites that 
protrude the cell (Figure 1-4; Lonergan et al., 2002). 
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Figure 1-4. Schematic of Homer-Wright rosettes. 
Homer-Wright rosettes are a cluster of neuroblasts (small uniform cells) that form a 
circular arrangement (arrow) around neurophil or neuritic processes (arrowhead) that 
are stained in red. Homer-Wright rosettes are characteristic of neuroblastomas and as 
such are used as a diagnostic tool. 
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1.3.10 Diagnosis 
Although understanding the histology of neuroblastomas is an invaluable tool for 
evaluating tumors, it is not the first step during diagnosis. The standard routine for 
diagnosing neuroblastoma usually begins with a physical exam accompanied by a urine 
test. Neuroblastomas produce elevated levels of catecholamines, which are small 
molecules such as dopamine and norepinephrine that function as the main 
neurotransmitters of the sympathetic nervous system. Catecholmaines are broken down 
into urinary metabolites (vanyllylmandelic acid and homovanillic acid) and measured in 
the urine (Brodeur, 2003). Ninety to ninety-five percent of neuroblastomas produce high 
levels of urinary metabolites (Kline and Sevier, 2003). 
Medical imaging also plays a pivotal role in the initial assessment of the neuroblastoma, 
indicating the precise location of the tumor (Howman-Giles et al., 2007). Computed 
tomography (CT) is an imaging method that generates two-dimensional images of the 
patient's body producing a cross-sectional view that when combined gives a three-
dimensional view. CT is mainly utilized for assessing tumors within the abdomen, 
pelvis, or mediastinum (Maris et al. , 2007). Another imaging technique used to examine 
the structure and function of the body is magnetic resonance imaging (MRI). MR1 is 
more effective than CT in providing contrast between the soft tissues of the body. MRl is 
the preferred method for determining the spread of the tumor into the spinal canal (Ishola 
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and Chung, 2007). Alternatively, CT can define the site and extent of the tillTior. In 
addition, CT can provide evidence of regional invasion, vascular encasement, 
adenopathy, and calcification (Howman-Giles et al., 2007). CT scans can determine if 
the tumor is neuroblastoma based on calcification evidence which occurs in over 80% of 
the patients (Howrnan-Giles et al., 2007). 
Another method for the clinical assessment of tumors is metaiodobenzylguanidine 
(MIBG) scintigraphy. MIBG is actively absorbed by catecholamine producing cells such 
as neuroblastoma. MIBG is a highly specific method of detection as it occurs in more 
than 90% of neuroblastomas (Maris et al. , 2007). 
1.3.11 Classification 
Following initial tillTior diagnosis, the histological features of the tumor are used to 
classify the tumor. In 1984, Shimada and colleagues developed a histopathological 
classification system that focused on NTs and related this information to the tumors 
clinical behavior (Castel et al. , 2007; Maris et al. , 2007). This age-linked classification 
system focused on the stromal development, the degree of neuroblast differentiation, and 
the nuclear morphology. Stromal development focused on the organizational pattern of 
the connective tissue. NTs divide into stroma-poor and stroma-rich groups (Shimada et 
al. , 1984). The degree of neuroblast differentiation was evaluated by microscopic 
assessment and refers to the level of neuroblastic cells maturity. An ' undifferentiated 
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population' contains less than 5% differentiating cells whereas a 'differentiated 
population' contains 5% or more differentiating cells (Shimada et al., 1984). The nuclear 
morphology is represented by the mitosis-karyorrhexis index (MKI). The MKI is defined 
as the number of mitoses and karyorrhexis (fragmentation of a cell's nucleus) per 5000 
cells. The MKI is divided into 3 classes: Low, less than 100 mitotic and/or karyorrhectic 
cells per 5000; Intermediate, 100 - 200 mitotic and/or karyorrhectic cells per 5000; and 
High, greater than 200 mitotic and/or karyorrhectic cells per 5000 (Shimada et al., 1984). 
The Shimada histopathologic classification can stratify tumors into either favorable or 
unfavorable categories based on age of the patient and subtype of NT (Joshi, 2000). 
In 1994, there was a consensus among six pathologists to create an International 
Neuroblastoma Pathology Committee. The intention of this committee was to 
standardize the terminology, as well as to create a morphological classification for the 
NTs. The committee used a modified version of the Shimada Classification system to 
develop the International Neuroblastoma Pathology Classification (INPC) which was 
proposed in 1999 (Shimada et al. , 1999b ). The INPC subdivided the stroma-rich group 
into ganglioneuroma, ganglioneuroblastoma-intermixed and ganglioneuroblastoma-
nodular. In addition, an age component was added to the stroma-poor I favorable group 
consisting of a <1.5 yrs and 1.5 - 5 years (Shimada et al. , 1999b; Vasudevan et al. , 2005). 
The MKI index is expressed as a percentage of mitosis and karyorrhexis where the low, 
intermediate and high MKI represent <2%, 2-4%, >4% respectively (Joshi, 2000). The 
INPC does not take into consideration the location of the tumor or the progression of the 
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disease during the time of diagnosis. Figure 1-5 outlines the various steps needed to 
classify and categorize the NTs according to INPC (Joshi, 2000). 
The International Neuroblastoma Staging System (INSS) was created in 1988 but 
underwent modifications and was not fully developed until 1993. The INSS is currently 
used as a part of the diagnosis and treatment of neuroblastoma patients (Brodeur et al., 
1993; Castel et al., 2007). The INSS consists of four stages (one through fom) including 
two subsets (2B and 4s) of neuroblastoma. The INSS represents the various ways NB 
tumors are diagnosed and treated. Simplistically, Stage l tumors are defined as localized 
and confined to the area of origin. Stage 1 tumors are usually removed by smgery alone. 
Stage 2A, the tumor is confined to one side of the body and cannot be completely 
removed by surgery alone. Also, lymph nodes enclosed within the tumor may contain 
neuroblastoma but lymph nodes outside the tumor are negative for neuroblastoma. Stage 
2B, the tumor is confined to one side ofthe body and cannot by completely removed by 
surgery alone. In addition, nearby lymph nodes are positive for neuroblastoma. Stage 3 
the cancer ca1mot be completely removed by surgery alone as it has infiltrated across the 
midline. The smrounding lymph nodes may or may not be positive for neuroblastoma. 
36 
Figure 1-5. Brief outline of the pathological prognostic categorization of NTs. 
NT classification is a complex process that requires a specific prognostic categorization 
protocol. Initially, the type of NT (neuroblastoma, NB; ganglioneuroblastoma, GNB; 
ganglioneuroma, GN) is defined. Then, subtypes of the tumor are identified. For GNB 
and maturing GN, age is not considered. However, age and subtypes of NB are 
considered when defining favorable histology (FH) or unfavorable histology (UH). The 
FH and UH classifications are then used in defining the neuroblastoma risk groups (see 
Table 1-1). 
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Stage 4, describes cancer that has metastized to the distant lymph nodes, bone, liver, skin, 
bone marrow or other organs. Stage 4S also called 'special' neuroblastoma occurs in 
children less than one year of age and is usually localized to one area of the body. 
However, the cancer may spread to the other side of the body or may spread to the liver, 
skin, and/or bone marrow (no greater than 10% of the marrow cells are cancerous). 
The Risk Group Classification system is an extension of the INSS that focuses on tumor 
location and progression (Children 's Oncology Group [COG]). Risk Group 
Classification is used to determine the most effective treatment for patients. This 
classification encompasses the stage of the disease (or INSS), age at diagnosis, MYCN 
status, DNA ploidy, and tumor histopathology (Table 1-1; Brodeur, 2003; Goldsby and 
Matthay, 2004; Vasudevan et al. , 2005; Maris et al. , 2007; Bowen and Chung, 2009). 
Children with neuroblastoma will be assigned into either the low-risk, intermediate-risk 
or high-risk group. 
In an attempt to gain global solidarity, a working group was assembled in 2005 to 
develop an International Neuroblastoma Risk Group (INRG) classification system. The 
INRG represented members from the major pediatric oncology group worldwide (Maris 
eta!., 2007). The INRG schema will include the International Neuroblastoma Risk 
Group staging system (INRGSS), MYCN status, Ploidy, Histology, age at diagnosis 
















0-21 years None 
Age <1 year None 
or 
Age 1-21 years 
andMNA 
or 
age 1-21 year 
andMA + FH 
None Age <1 year and 
MNA 
or 
age 1 - 21 years 
andMNA +FH 
None Age <1 year and 
MNA 
Age <1 year and Age <1 year and 
MNA +FHand MNAandDI= l 
DI>1 or 
Age <1 and MNA 
+ UH 
Table 1-1. Neuroblastoma risk groups. 
None 
Age 1-21 years 
andMA +UH 
Age 0-21 years 
andMA 
or 
age 1 - 21 years 
andMNA + UH 
Age < 1 year and 
MA 
Age <1 and MA 
The low, intermediate, and high risk groups are based on based stage, age, MYCN status, 
histological categories, and DNA ploidy. 
MA, MYCN amplified; MNA, non-MYCN amplified; Dl, DNA index (ploidy); FH, 
favorable histology; UH, unfavorable histology. 
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As mentioned earlier, the INSS is currently still in use. The INRG is also developing the 
INRGSS which will now use image-defined risk factors along with bone marrow 
morphology to aid in the definition of the disease (Castel et al. , 2007; Maris et al., 2007). 
The new staging system will be classified into four divisions representing Stage L 1, Stage 
L2, Stage M and Stage MS. Stage L 1 represents localized disease without image-defined 
risk factors whereas stage L2 represents localized disease with image-defined risk factors 
(Cohn et al., 2009; Monclair et al., 2009). Stage M represents tumors that are widely 
metastatic whereas stage MS represents tumors that have a 4S INSS pattern (Maris et al. , 
2007). As mentioned earlier, the INRG and INRGSS classification systems are a work in 
progress with a final outline of the criteria yet to be determined. Nevertheless, further 
refinement of these risk group will ultimately improve clinical interpretation (Maris et al. , 
2007). 
1.3.12 Treatment 
As mentioned, before treatment strategies are considered the patients are assigned a risk 
group classification (Howman-Giles et al., 2007). The low-risk group includes localized 
or stage 4S neuroblastomas can regress spontaneously or differentiate into benign 
ganglioneuroblastoma or ganglioneuroma tumors. The regression response by certain 
subsets of neuroblastoma is approximately ten to one hundred times more than any other 
cancer (Castel et al. , 2007). Treatment for the low-risk group would usually involve 
minimal therapy such as surgery. Treatment for the intermediate-risk group would likely 
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contain a combination of surgery and chemotherapy. The high-risk group contains stage 
3 or 4 neuroblastoma tumors that are widely metastatic and have poor outcomes despite 
aggressive therapy (Brodeur, 2003). These tumors are fatal in approximately 60% of the 
high risk cases (Castel et al. , 2007). It is also worth mentioning that fifty percent of all 
neuroblastoma cases are classified as high-risk for recurrence (Maris et al. , 2007). 
Treatment for the high-risk group usually consists of a combination of chemotherapy, 
radiation therapy, surgery, stem cell transplant and biological based approaches (Joshi, 
2000; Brodeur, 2003; Castel and Canete, 2004). Aggressive chemotherapy in young 
infants can lead to severe mental and physical impairments and poor quality of life that 
adds further burden to patients, families, and health care systems. Despite this intensive 
multi-modal approach, approximately 70% of those neuroblastoma cases still remain 
incurable (Wei et al., 2005; Maris et al., 2007). New approaches involving cytotoxic 
agents, immunotherapy, retinoids, angiogenesis inhibitors, and tyrosine kinase inhibitors 
are currently being evaluated (Maris et al., 2007). 
In 2008, the International Society of Pediatric Oncology (SlOP) group completed a phase 
III clinically trial for high-risk neuroblastoma patients. The focus of this trial was to test 
the effects of the Ch14.18 antibody on high-risk neuroblastoma patients1• Ch 14.18 is a 
chimeric mouse I human monoclonal antibody that binds tumors over-expressing 
ganglioside GD2 and induces cell-mediated cytotoxicity2. The outcome of the antibody-
1 www .cancer .gov/searchNiewCI inica1Trials .aspx?cdrid=6919l &version=HealthProfessional&protocolsear 
chid=40 15135 (retrieved on February 17, 2009) 
2 www.cancer.gov (retrieved on February 17, 2009) 
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based immunotherapy was very effective for the high-risk neuroblastoma patients. The 
progression-free survival and overall survival at 2 years were 20 percent and 11 percent, 
respectively, more effective than standard treatments3. 
Presently, standard treatments for neuroblastoma include the use of retinoids because of 
their role in normal neural crest development. A randomized clinical trial has previously 
shown that 13-cis RA, an isomer of all-trans RA (ATRA), improved the survival rates 
while reducing toxicity in high-risk patients (Matthay et al., 1999). The ability of the 
aggressive neuroblastoma tumors to differentiate into benign ganglioneuromas is a vital 
part ofthe treatment. Consequently, 13-cis RA has been included as part of the treatment 
regiment for high-risk neuroblastoma cases. The naturally occurring active form of RA, 
A TRA, has been extensively studied in culture. The ability to transform neuroblastoma 
cells into a more differentiated state is observed with differentiation markers such as 
neurofilaments (Hill and Robertson, 1997; Ross et al. , 2002). 
Despite advancements in treatment, neuroblastoma still accounts for 15% of cancer 
deaths in children (Maris et al. , 2007). More effective diagnostic tools and treatments are 
needed to improve cure rates, reduce toxicity, and long-term effects of current therapies. 
Discovering novel treatments for NTs will require new insight into the interaction 
between existing molecular pathways and new molecular markers. New markers will 
provide better tools for selecting the best treatment for the neuroblastic patient. 
3 www .asco.org (retrieved on August 13/09) 
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1.4 Tube down 
Our laboratory isolated and characterized a developmentally regulated gene named 
TUBEDOWN. TUBEDOWN is found on chromosome 4 and is located at 4q31.1. There 
are two protein isoforms of TUBEDOWN, Tubedown-1 (Gendron eta!., 2000) and 
Tubedown-1 00 (Fluge eta!., 2002; Paradis et al., 2008). Both forms are similar to the 
Yeast N-terminal acetyltransferase subunit Nat1 (28% Tubedown-1 & 25% Tubedown-
1 00). The Tubedown-1 00 protein harbors two different types of conserved domains 
including 3 full tetratricopeptide repeat (TPR) motifs (TPRI: ll-112aa, TPR2: 115-
213aa; TPR3: 3 78-4 70aa) and a coiled-coil domain homologous to a syntaxin 18 
conserved domain (503-676aa) (Figure 1-6A; H. Paradis, personal communication). The 
TPR domains mediate protein-protein interactions (Blatch and Lassie, 1999) and their 
presence in Tubedown suggests that this protein may be part of a multi-protein complex 
(Gendron et al., 2000; Fluge et al. , 2002). Syntaxin-18 is a member of the syntaxin 
family, which are involved in membrane trafficking (Hatsuzawa et al. , 2000). Recently, 
the neuroblastoma-amplified gene (NAG) and ZW1 0 were reported to be components of 
the syntaxin-18 complex (Aoki et al. , 2009). NAG has been shown to be associated with 
poor prognosis (Kaneko eta!., 2007). However, there is controversy surrounding the 
association ofNAG with tumor progression and outcome (Aoki eta!., 2009). In addition, 
ZWlO plays a role in turning off spindle checkpoint (Williams et al., 2003). Collectively, 
these studies suggest a role for the syntaxtin-18 complex in cell proliferation. 
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Fluge and colleagues used a nested RT-PCR approach to show that alternative splicing 
did not affect the ORF ofTubedown-100 (Fluge eta!., 2002). Therefore, Tubedown-1 
and Tubedown-1 00 are likely derived from the same transcript (Fluge eta!. , 2002; Willis 
et al., 2002; Sugiura et al., 2003). In addition, our laboratory obtained evidence that both 
Tubedown isoforms can be derived from the same transcript (H. Paradis, personal 
communication). At the protein level, Tubedown-1 has been suggested to result from an 
alternative translation initiation (Fluge et al., 2002). Tbdn-1 00 may contain an alternative 
start site such as an Internal Ribosome Entry Site (IRES). IRES is a nucleotide sequence 
that allows for translation initiation of a specific mRNA sequence. IRES acts in a cap-
independent manner and are commonly located within the 5' -UTR (Baird et al. , 2006). 
Tubedown-1 00 encodes an 866aa protein (Figure 1-6A) with a molecular weight of 
1 OOkDa (Fluge et al., 2002) whereas Tubedown-1 encodes a 594aa protein (Figure 1-6B) 
with a molecular weight of 69kDa (Gendron et al., 2000). 
Tubedown-1 00 is a functional protein that binds to the Ard1 protein (Park and Szostak, 
1992; Sugiura eta!., 2003; Arnesen eta!. , 2005a; Arnesen et al. , 2008). Recently, 
Tubedown-1 00 was shown to be present in a complex with cortactin, an actin binding 
protein (Paradis eta!., 2008). Tubedown-1 00 was reported to co-localize with cortactin, 
which is important for endothelial permeability, vesicular transport, and cell migration 
(Buday and Downward, 2007; Paradis eta!., 2008). In addition, cortactin has a possible 
role in tumor invasion through cell motility structures as lamellipodia and invadopodia 
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Figure 1-6. Tuhedown-1 and Tuhedown-1 00 domains. 
(A) Tubedown-100 encodes a protein (866aa) whereas Tuhedown-1 (B) encodes a 
protein of 594aa. The TPRs represent tetratricopeptide repeat motifs whereas the 
syntaxin domain represents a coiled-coil motif. Various antibodies were utilized in 
assessing Tubedown junction and a schematic representing the location of the antibodies 
are shown (C). The asterisks(*) corresponds to the aa sequence recognized by the 0£5 
antibody (J0-20aa), the pound symbol(#) corresponds to the aa sequence denoted by the 
Ab1272 antibody (J60-1 70aa), and the ampersand symbol(&) corresponds to the aa 
sequence represented by the Misty antibody (483-494aa). 
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(Weaver, 2008). Also, over-expression of cortactin has been reported in many human 
cancers including head and neck squamous cell carcinomas, colorectal, gastric, breast and 
ovarian cancers (Buday and Downward, 2007; Weaver, 2008). 
Tbdn-100 (Tbdn, also known as NATH and NARGl) and Ardl form a functional 
acetyltransferase NatA complex that is evolutionarily conserved from yeast to human. 
Mutagenesis studies completed in yeast have previously shown that this functional Nat l-
Ard I complex is involved cell cycle control, cell growth, and sporulation (Mullen et al. 
1989). Park and Szostak showed in yeast that both Natl and Ard 1 are required to form a 
functional acetyltransferase complex (Park and Szostak, 1992). Sugiura and colleagues 
used a murine model to demonstrate the involvement of Tbdn and Ard 1 during brain 
development as well as during neuronal tissue development (Sugiura et al. , 2003). In 
2005, Arnesen et al. identified and characterized the human Nat-Ardl acetyltransferase 
complex (Arnesen et al. , 2005a). In yeast, the NatA complex appears to have a role in 
ribogenesis as it binds the nascent polypeptide-associated complex and associates with 
ribosomes (Gautschi et al. , 2003 ; Arnesen et al. , 2005a; Raue et al. , 2007; Polevoda et al. , 
2008). Recently, Arnesen and colleagues demonstrated that yeast and human NatA 
subunits are phenotypically similar. As well, the human ARDJ and NATJ genes 
complement the yeast Ardl and Nat] genes. However, heterologous combinations (such 
as hArdl and yNatl) between the species proved non-functional in yeast. Although the 
proportion of acetylation varied between yeast and human, NatA was still able to 
acetylate the same substrates in both species (Arnesen et al. , 2009). 
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A third subunit of the yeast NatA complex, Nat5, was identified (Polevoda and Sherman, 
2003). Gautschi and colleagues demonstrated that the association of the Nat l-Ard I-Nat5 
complex with the ribosome depended on the presence ofNatl and not Ardl or Nat5 
(Gautschi et al., 2003). In particular, Natl appears to have a role in the binding and/or 
positioning of the complex to the ribosomes (Gautschi et al., 2003). In 2006, the human 
homologue of the yeast Nat5p was described as hNAT5 (Arnesen et al., 2006a). The 
NatA complex has been shown to be located within the cytoplasm (Gautschi et al., 2003 ; 
Arnesen et al., 2006a). In other mammalian cells, homologues for human TBDN 
(mNAT2, 70% identity) and ARD1 (ARD2, 81% identity) were reported (Sugiura et al. , 
2003; Arnesen et al., 2006b). 
Both yeast and mammalian Tbdnl Ard 1 protein complexes appear to possess factor 
acety I transferase (FAT) activity, which target cytoplasmic proteins, as opposed to histone 
acetyltransferases (HATs). Although the in vivo acetylated substrates of the Tbdn 
complex in cells have not yet been identified, Tbdn was found to associate with the actin 
binding protein cortactin in retinal endothelial cells, a cell type in which Tbdn exerts a 
homeostatic influence (Wallet al., 2004; Paradis et al., 2008). Cortactin is important for 
cellular permeability (Mehta and Malik, 2006) and knockdown ofTbdn expression both 
in vitro and in vivo leads to an increase in endothelial cell permeability (Paradis et al., 
2008). To study the functional importance ofTbdn, our laboratory generated three 
different Tbdn antibodies (Figure 1-6C). The Misty and Ab 1272 antibodies were used to 
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detect protein levels by Western blot analysis whereas the OES antibody was used to 
detect the level of protein expression by immunohistochemistry. 
Tbdn is most highly expressed during embryonic development (mid to late gestation in 
mesenchymally derived cells such as endothelial, chondrocytic, hematopoietic and 
osteoblastic cells) and in neuronal cells (Sugiura et al., 2003; Ohkawa et al., 2008). 
However, in adult, high levels of Tbdn is restricted to very few tissues including the cells 
of bone marrow, ocular blood vessels, endothelial choroid plexus, and blood vessels of 
regressing ovarian follicles (Gendron et al., 2000; Gendron et al., 2001 ; Paradis et al., 
2002; H. Paradis, personal communication). In humans, a low level of Tbdn expression 
was present in most adult tissues. 
Tbdn is transiently expressed during the developing vasculature tissue with high levels of 
Tbdn expression found postnatally in the ocular endothelium and blood vessels of 
regressing ovarian follicles (Gendron et al., 2000; Gendron et al., 2001; Paradis et al. , 
2002). Tbdn has been extensively characterized as a negative regulator of angiogenesis 
in endothelial cells (Gendron et al. , 2000; Gendron et al., 200 l; Paradis et al., 2002). In 
addition, decreased Tbdn levels were demonstrated in the retinal blood vessels of patients 
with proliferative diabetic retinopathy (Gendron et al., 2001). A bitransgenic mouse 
model was used to suppress Tbdn levels within the endothelial cells, resulting in retinal 
neovascular pathology (Wallet al., 2004). The abovementioned studies suggest that at 
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least in the retinal endothelial cells, Tbdn participates in promoting vascular homeostasis 
in the retina. 
In addition, there is evidence that Tbdn could have different functions in other cellular 
contexts such as the developing neuronal tissue (Sugiura et al., 2003). Sugiura and 
colleagues showed that both Tbdn and Ardl demonstrated a spatia-temporal up-
regulation during brain development (Sugiura et al. , 2003). Additionally, a 2-fold 
decrease in Tbdn and Ardl levels occurred upon RA-induced differentiation of mouse 
P 19 embryonic carcinoma cells (Sugiura et al., 2003). 
The Tbdn-Ardl (NatA) complex also appears to have a role in tumorigenesis (Arnesen et 
al. , 2006c). siRNA knockdown ofTbdn and Ard 1 expression in HeLa cells reduced cell 
viability. The decrease in cell viability was attributed to an increase in apoptosis and not 
a reduction in cell proliferation. 
In 2002, the original connection between Tbdn and cancer was established. Tbdn was 
up-regulated in gastric cancer and over-expressed in thyroid carcinoma tissue when 
compared to non-neoplastic thyroid tissue (Fluge et al. , 2002; Line et al., 2002). 
Moreover, high expression of the Tbdn transcript was linked to the clinically aggressive 
thyroid tumors which contained poorly differentiated or undifferentiated areas (Fluge et 
al. , 2002; Arnesen et al. , 2008). In the same report, a Burkitt lymphoma cell line, 
characterized by a high proliferation rate, was shown to exhibit elevated levels of Tbdn 
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expression compared other adult tissues including the human brain, the heart and the 
normal thyroid (Fiuge et al., 2002). 
The second part of the NatA complex, Ard 1, plays a role in cellular viability (Arnesen et 
al., 2008). In 2005, RNAi was used to knock-down hArd I expression in human 
hepatocellular carcinoma (HepG2) cells, resulting in a reduction in cell division (Fisher et 
al. , 2005). A decrease in cell viability and an increase in apoptosis occurred during 
siRNA-knockdown of hArdl and Nath in human cervical (HeLa) cells (Arnesen et al. , 
2006c ). In addition, induction of G 1 arrest and inhibition of cell proliferation occurred in 
lung cancer cells (H 1299 and A549) upon treatment with hArd !-silencing RNA (Lim et 
al. , 2006). Recently, ARDl was reported differentially expressed in stage 4 
neuroblastomas compared to stage 4S neuroblastomas (Lavarino et al., 2009). 
As mentioned, Tbdn expression is linked to gastric cancer and thyroid carcinoma. The 
more aggressive thyroid cancers have higher levels of Tbdn expression. In addition, 
Tbdn expression is tightly down-regulated following embryonic neural development. 
Therefore, Tbdn may play an important role in neural crest cancers such as 
neuroblastoma, which are thought to result from derangements in the normal 
differentiation process. Previously, our laboratory had shown that Tbdn was expressed in 
neuroblastoma cells (H. Paradis, personal communication). However, the role ofTbdn in 
neuroblastic cells remains elusive. 
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1.5 Hypothesis & Objectives 
Tbdn expression is tightly down-regulated following embryonic neural development. 
Therefore, my central hypothesis is that the persistence of Tbdn is an important factor in 
neural crest tumors such as ganglioneuroma, ganglioneuroblastoma, and neuroblastoma, 
which are thought to result from derangements in the normal differentiation process. 
My first objective was to determine if Tbdn expression is linked to the differentiation 
status and aggressiveness ofNTs. Amplification and over-expression of MycN have 
been widely known to contribute to the growth (Weiss et al. , 1997) and the 
aggressiveness (Brodeur, 2003; Wei et al., 2008) of neuroblastoma. My second objective 
focused on the regulation of Tbdn. I wanted to determine if there was a correlation 
between MycN and Tbdn. The 5' -UTR I promoter region of TBDN contained a canonical 
E-box motif which was a binding site for MycN. Therefore, my focus was on 
determining ifMycN binds directly to the TBDN promoter region. If so, then is it 
possible that this relationship between MycN and TBDN could be responsible for 
contributing to the aggressiveness of neuroblastoma? 
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2.1.2 Abstract 
Purpose: The discovery and validation of new prognostic factors and further 
refinement of risk group stratification are needed to improve clinical 
interpretation of neuroblastoma. Our laboratory isolated and characterized a 
developmentally regulated gene named TUBEDOWN against which we have 
raised a monoclonal antibody (OE5). Tubedown becomes downregulated 
postnatally yet remains strongly expressed in some neuroblastomas. The 
purpose of this study is to define the utility ofTubedown expression as a new 
measure of the differentiation status and aggressiveness of neuroblastic tumors. 
Experimental Design: Tubedown protein expression was quantitatively 
assessed in neuroblastic tumors (neuroblastomas, ganglioneuroblastomas, and 
ganglioneuromas) and normal adrenal tissues using Western blot and OE5 
immunohistochemistry. Regulation of Tubedown expression during retinoic 
acid-induced neuronal differentiation in neuroblastoma cell lines was assessed 
by Western blotting. 
Results: High levels ofTubedown expression are observed in tumors with 
significant neuroblastic component, unfavorable histopathology, advanced 
stage, high-risk group and poor outcome. In contrast, more differentiated 
subsets of neuroblastic tumors, ganglioneuroblastomas with favorable 
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histopathology and ganglioneuromas, express low levels of Tubedown. In vitro, 
marked retinoic acid-induced neuronal differentiation responses of 
neuroblastoma cells are associated with a significant decrease in Tubedown 
expression while limited neuronal differentiation responses to retinoic acid were 
associated with little or no decrease in Tubedown expression. 
Conclusions: Our results indicate that the levels of Tubedown expression are 
linked to the differentiation status and aggressiveness of neuroblastic tumors 
and represent an independent prognostic factor for neuroblastoma. Tubedown 
expression may be useful to more accurately define different neuroblastic tumor 
subsets and ultimately provide more adequate assessment and treatment for 
neuroblastoma patients. [Clin Cancer Res 2007; 13 (5) 1480-1487} 
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2.1.3 Introduction 
Neuroblastoma is one of the most common solid tumors occurring in children (Castel and 
Canete, 2004). Although the etiology ofNB is still not clear, evidence suggests that these 
neuro-ectodermal tumors arise in the sympathetic nervous system from a defect occurring 
during normal developmental processes (Brodeur, 2003; van Noesel and Versteeg, 2004; 
Maris, 2005; Vasudevan et al., 2005). Neuroblastomas exhibit heterogeneity with respect 
to differentiation and tumor progression, making diagnosis and treatment a challenge 
(Brodeur, 2003; Browne et al., 2006). In young infants, localized and stage 4S 
neuroblastoma can spontaneously undergo complete regression or differentiate into 
benign ganglioneuroma requiring minimal treatment (Brodeur, 2003). Conversely, 
children with advanced metastatic neuroblastoma have poor outcomes despite intensive 
multimodality therapies (Castel and Canete, 2004; Laverdiere et al., 2005). In recent 
years, choice of treatment for neuroblastoma has relied on a range of prognostic factors 
(age at diagnosis, International Neuroblastoma Staging System, histopathological features 
[International Neuroblastoma Pathology Classification] , DNA ploidy, and MYCN 
amplification status) that have been used to stratify these tumors into low-, intermediate-, 
or high-risk categories (Maris, 2005; Vasudevan et al. , 2005). However, both the 
validation of these prognostic factors and further refinement of risk group stratification 
are needed to improve clinical interpretation (Maris, 2005; Vasudevan et al. , 2005). 
Despite advancements in treatment, neuroblastoma still accounts for 15% of cancer 
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deaths in children (Maris, 2005). Therefore, more effective diagnostic tools and 
treatments are needed to improve cure rates, reduce toxicity and long-term effects of 
current therapies (Brodeur, 2003 ; Castel and Canete, 2004; Maris, 2005). 
Neuroblastoma differentiation is likely an important biological process that can impact 
tumor outcome (Shimada et a!., 1999a; Shimada et a!., 1999b ). The use of differentiating 
agents is effective in improving the survival rate of high-risk neuroblastoma patients 
while limiting toxicity in normal host cells (Castel and Canete, 2004). One such 
commonly used differentiation agent is retinoic acid. Retinoic acid is one of the most 
powerful in vitro differentiating agents of neuroblastoma cells (Reynolds et a!. , 2003). 
The monitoring of neuroblastoma differentiation using specific differentiation markers 
could be useful in predicting neuroblastoma outcome. 
Our laboratory isolated and characterized a developmentally regulated gene named 
TUBEDOWN (Gendron eta!., 2000). Tubedown-1 has been defined as a protein of 
69kDa with homology to yeast Natl , a subunit of the yeast acetyltransferase NatA 
(Gendron et a!. , 2000). A longer 1 OOkDa variant of Tubedown-1, Tubedown-1 00, 
appears to be derived from the same transcript (Fluge eta!., 2002; Willis et al., 2002; 
Sugiura et al., 2003). Tubedown is transiently expressed during embryogenesis in several 
tissues while in adults high levels are found in only a few tissues including bone marrow, 
ocular endothelial cells, atrial endocardium, and blood vessels of regressing ovarian 
follicles (Gendron eta!., 2000; Gendron et al., 2001). TUBEDOWN transcript is also 
58 
expressed in neuronal cells during brain development but suppressed during neuronal 
maturation (Sugiura et al., 2003). TUBEDOWN is also highly expressed in papillary 
thyroid carcinoma cells while adult tissues except testis express low levels (Fluge et al. , 
2002; Arnesen et al., 2005b). We have extensively characterized Tubedown as a negative 
regulator of angiogenesis in endothelial cells (Paradis et al., 2002; Wall et al., 2004). 
However, Tubedown could have different functions in other cellular contexts (Willis et 
al. , 2002; Arnesen et al. , 2006c). Since TUBEDOWN expression is tightly down-
regulated following embryonic neural development, I hypothesized that the persistence of 
Tubedown may be an important factor in pediatric tumors such as neuroblastoma which 
are thought to result from derangements in normal differentiation processes. The present 
study addresses a hypothesis that levels of Tubedown expression are linked to the 
differentiation status and aggressiveness of neuroblastic tumors and could represent an 
independent prognostic factor for neuroblastomas. 
2.1.4 Materials & Methods 
Tumor Specimens - Snap frozen tissues and paraffin embedded sections from 
neuroblastoma, ganglioneuroblastoma and ganglioneuroma were obtained from the 
Cincinnati Children's Hospital Medical Center (Cincinnati, OH), the Brain Tumor Tissue 
Bank (London, ON, Canada) and the Janeway Child Health Centre (St. John's, NL, 
Canada). Two tissue microarrays were constructed using triplicate I.Omm cores taken 
from 45 paraffin-embedded, formalin-fixed neuroblastic tumors (30 neuroblastoma, 7 
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ganglioneuroblastoma, 7 ganglioneuroma, and 5 composite/mixed histology tumors), 5 
normal adrenal glands, and 20 other neural crest-derived and unrelated neoplasms 
obtained from archival material at the University of Michigan and the Cooperative 
Human Tissue Network (National Cancer Institute). Specimens from the tissue 
microarrays had previously been classified according to International Neuroblastoma 
Pathology Classification criteria (Shimada et al. , 1999a; Shimada et al., 1999b) and 
clinical data (age at diagnosis, sex, stage, treatment protocol, initial response to treatment, 
event-free survival, time to relapse, and time to death) was made available. All human 
specimens were obtained and studied under the approval of the Institutional Review 
Boards of the author' s institutions. 
MYCN fluorescence in situ hybridization- Analyses were performed on representative 
sections (Bridge eta!., 2006). A commercial probe cocktail was used, consisting of a 
Spectrum OrangeTM-labed centromere enumerating probe 2 paired with a Spectrum 
GreenTM-labeled MYCN probe on 2p24 (Vysis, Inc. , Downers Grove, IL). The probes 
were diluted 1150 with tDenHybTM hybridization buffer (lnsitus Biotechnologies, 
Albuquerque, NM). For each hybridization, 100 non-overlapping nuclei were 
enumerated for MYCN and centromere enumerating probe 2 signals. Cells with MYCN to 
centromere enumerating probe 2 ratios >4 or innumerable MYCN signals were considered 
amplified. In non-an1plified cases, those with > 10% cells containing >2 copies of 
centromere enumerating probe 2 were defined as having polysomy 2. 
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Cell Cultures - LA-N-5 (Seeger et al. , 1982a) and IMR-32 (Tumilowicz et al., 1970) cell 
lines were gifts from Dr. Thomas Inge (Cincinnati Children's Hospital Medical Center, 
Cincinnati, OH). The LA-N-5 and IMR-32 cells were respectively maintained in RPMI 
1640 and in Dulbecco's Modified Eagle Media supplemented with 10% heat-inactivated 
fetal bovine serum and 2mM glutamine. The SK-N-DZ and RF/6A (rhesus macaque 
choroid-retina endothelial) cell lines were acquired from the American Type Culture 
Collection and maintained, respectively, in RPMI 1640 and in Dulbecco' s Modified 
Eagle Media supplemented with I 0% fetal bovine serum, 0.1 mM non-essential amino 
acids and 4mM glutamine. The EWS-96 cell line was derived from a tumor specimen 
obtained from a patient with Ewing's sarcoma and will be described elsewhere. 
Exponentially growing cells were used for every experiment. 
All-trans retinoic acid (Sigma) was dissolved in 5% dimethylsulfoxide and added to cells 
at an optimal concentration of 41-lM. The media (with or without retinoic acid) was 
changed every 3 days. Cells were photographed using a Leica DMIRE2 microscope 
system with a Qlmaging RETIGA Exi camera and Openlab software. Viability was 
assessed using trypan blue dye exclusion. All cell growth assays were performed in 
triplicate. 
Western Blot - Celllysates were prepared from snap frozen tumor specimens and cell 
lines as previously described (Gendron et al., 2000). Protein lysates were quantified 
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using albumin as standard and analyzed by SDS-PAGE. Western blotting was performed 
by standard procedures using ECL Plus chemiluminescence detection reagent 
(Amersham Biosciences) for anti-NF-M (Zymed Laboratories), vimentin (Ab-1) 
(Oncogene Research Products), c-Myb (C-19) (Santa Cruz Biotechnology) and anti-
MycN (EMD Biosciences) antibodies. Ab1272 anti-Tubedown Western blot analyses 
were performed as described (Gendron et al., 2000; Gendron et al., 2001). All Western 
blots were stripped and reprobed with either ERK-1 (Santa Cruz Biotechnology) or 
alpha-Tubulin (Sigma) antibodies. 
Tubedown Immunohistochemistry - Sections from paraffin embedded tissues were 
deparaffinized, post-fixed in 4% paraformaldehyde and incubated overnight with anti-
Tubedown mouse monoclonal OE5 supernatant or negative control supernatant 
supplemented with control isotype match IgG2a antibody (Dakocytomation) in 3% non-
fat milk in Tris buffer saline with 0.05% Tween 20. The mouse monoclonal OE5 
hybridoma (Wall et al., 2004) recognizes Tubedown recombinant protein. Sections were 
developed using alkaline phosphatase and Vector Red substrate kit (Vector Laboratories), 
and photographed in triplicate using a Leica DMIRE2 microscope system with a 
Qlmaging RETIGA Exi camera and Openlab software. 
Northern Blotting and Real-Time RT -PCR - Northern blotting was performed as 
previously described (Gendron et al. , 2000). Blots were hybridized with a 693bp 32P-
labeled MYCN eDNA probe (Image Clone ID 5502743) (American Type Culture 
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Collection) and reprobed with a mouse 18S ribosomal eDNA fragment in order to 
confirm loading equivalency and RNA integrity. Densitometric measurements of band 
intensity were completed using OptiQuant software. 
For RT-PCR analysis, eDNA was prepared from total RNA using Roche Reverse 
Transcription kit. The eDNA was then amplified by Real-Time PCR with primers 5'-
AAC CCC AAT GAT GAT GGA AA-3' and 5'- CCA AAG CAA TAG ATG GCT 
GA-3' specific for human Tubedown (GeneBank accession no. BC039818) using a 7000 
sequence detector system (Applied Biosystems). EWS-96 cells were used as a standard 
for the experiments. All experiments were done in at least triplicate. 
Data and Statistical Analyses - To stratify neuroblastoma patients into low-, 
intermediate- and high-risk groups, prognosis parameters including age at diagnosis, 
International Neuroblastoma Staging System, histopathology (International 
Neuroblastoma Pathology Classification), and MYCN amplification status were used as 
previously described (Maris, 2005). 
Tubedown immunostaining was quantified as previously described (Gendron et al., 
2006). Tubedown staining levels for each specimen were averaged and the average 
background levels subtracted. To standardize single tumors and tumors from the tissue 
microarrays, paraffin embedded sections from a Ewing's sarcoma xenograft tumor were 
used as a control in every experiment. Tubedown relative level of expression was 
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calculated from a ratio of expression of each specimen over that of the Ewing's sarcoma 
tumor. 
Quantitative analyses were compared using the two-tailed Student's t-Test with a 
Microsoft Excel program. Tests for homogeneity of variance were performed as 
described4 . The data was considered to be statistically significant if the p-value was less 
than or equal to 0.05. 





High levels of Tubed own expression in neuroblastic tumors correlates 
with advanced stages and neuroblastic unfavorable histopathology 
Western blotting showed that Tubedown is expressed in the LA-N-5 human 
neuroblastoma cell line and in several neuroblastoma tumor specimens (Figure 2-1). 
Much higher levels of Tubedown were detected in the stage 2 and 3 neuroblastoma 
specimens compared to stage 1 neuroblastoma specimens and ganglioneuroblastoma 
specimens (Figure 2-1 ). Additional neuroblastic tumor specimens were next analyzed for 
Tubedown expression by quantitative immunohistochemistry using anti-Tubedown OE5 
monoclonal antibody (Wallet al. , 2004) (Figure 2-2). In neuroblastoma, the cells that 
stained most intensely for Tubedown were of neuroblastic appearance (small round cells) 




Figure 2-1. Western blot analysis of Tubedown-1 expression in cell lines and primary 
neuroblastic tumors. 
Western blot analysis using Abl272 anti-Tubedown (Tbdn-1) antibody(69 kDa) of LA-N-
5 and RF/6A eel/ lines, and neuroblastoma and ganglioneuroblastoma pathology 
specimens. ERK (44/42 kDa) western blot analysis was used to show loading 




Figure 2-2. Immunohistochemistry analysis ofTubedown expression in neuroblastic 
tumors and normal tissues. 
Tubedown immunohistochemistry on primary neuroblastoma tumors (stage 1 [A}, stage 2 
[B), stage 3 [C) and stage 4 [D and H)), stroma rich (favorable histopathology) primary 
ganglioneuroblastoma tumor (F), primary ganglioneuroma tumor (G) and normal 
adrenal tissues (E). Specimens were stained with anti-Tubedown 0£5 monoclonal 
antibody (A-G and inset from panel H) or control with isotype matched negative control 
antibody (H) and developed using alkaline phosphatase (bright red). Representative 
experiments are shown at 400X magnification. Arrows indicate positively stained cells 
while arrowheads indicate absence of staining in structures such as blood vessels. The 
scale bar represents JOOJ.lf'1. 
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(Figure 2-2). Normal adrenal tissues contained significantly lower Tubedown staining 
(0.62 +/- 0.11 relative units) than stage 2, 3 and 4 neuroblastoma tumors (p=0.047, 
p=0.036 and p=3.4 x 10-6 respectively) (Figure 2-2 and 2-3A). Moreover, stage I and 2 
neuroblastoma exhibited significantly lower levels of Tubedown immunostaining (0. 97 
+/- 0.10 and 1.04 +/- 0.13 relative units, respectively) than the advanced stage 3 and 4 
neuroblastoma tumors (1.34 +/- 0.26 and 1.41 +/- 0.05 , respectively; p =6.8 x l0-14) 
(Figure 2-2 and 2-3A). 
In the more differentiated neuroblastoma subtypes (ganglioneuroblastoma and 
ganglioneuroma), both ganglion-like and stromal (Schwann-like) cells faintly stained for 
Tubedown at levels lower than the neuroblastic- like cells observed in neuroblastoma 
specimens (Figure 2-2 and 2-3A). Interestingly, two out of two nodular 
ganglioneuroblastoma specimens with unfavorable histopathology and significant 
neuroblastic component expressed much higher levels of Tubedown in neuroblastic-like 
cells (1.57 +/- 0.06 relative units) than all favorable ganglioneuroblastoma specimens 
with minimal neuroblastic component (0.65 +/- 0.10) (Figure 2-2 and 2-3A). 
Significantly lower levels of Tubedown expression in the ganglioneuroma specimens 
(0. 72 +/- 0.11 relative units) and ganglioneuroblastoma specimens with favorable 
histopathology and minimal neuroblastic component were observed compared to the 
advanced stage 4 neuroblastoma tumors (p=6.0 x 10-6 andp=O.OOll, respectively) 
(Figure 2-3A). Although the more differentiated ganglioneuroma and 
ganglioneuroblastoma tumors with minimal neuroblastic component express lower levels 
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Figure 2-3. Quantitative analysis of Tubedown expression in neuroblastic tumors. 
A) Levels ofTubedown (Tbdn) expression in normal adrenal tissues (Normal, n=4) and 
neuroblastic tumors (ganglioneuroma, n =6; ganglioneuroblastoma with favorable 
histopathology: ganglioneuroblastoma, n=6; ganglioneuroblastoma with unfavorable 
histopathology and significant neuroblastic component: ganglioneuroblastoma(n), n=2; 
neuroblastoma tumors stage 1: Sf, n=9; neuroblastoma tumors stage 2: S2, n=5; 
neuroblastoma tumors stage 3: S3, n=2; and neuroblastoma tumors stage 4: S4, n=l 1). 
B) Significantly higher levels ofTubedown (Tbdn) expression were present in the 
unfavorable neuroblastoma specimens (n = 13) compared to the favorable neuroblastoma 
(n =l 7). C) Kaplan-Meier analysis displaying the correlation between low Tubedown 
(Tbdn) expression in neuroblastoma specimens and overall survival (p=0.038 at 3 years). 
Low expression levels (<1.3 relative units, n=9) versus high expression levels (?.1 .3 
relative units, n=13). D) Significantly lower levels ofTubedown (Tbdn) expression were 
present in the low-risk group neuroblastoma specimens (n= 14) compared to the high-risk 
group neuroblastoma (n =11). In panels A, Band D the relative Tubedown expression 
units for each specimen is represented by a small dot, while the averages of Tubedown 
levels for each category are represented by large squares. The bars represent standard 
error of the mean. 
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of Tubedown than neuroblastoma specimens, the differentiation status within 
neuroblastoma specimens, categorized according to the International Neurobla toma 
Pathology Classification system, was not associated with a significant difference in 
Tubedown levels. The undifferentiated neuroblastoma specimens expressed 1.18 +/- 0.13 
relative units of Tubedown, while the differentiated and poorly differentiated 
neuroblastoma specimens expressed respectively 1.12 +/- 0.09 and 1.18 +/- 0.13 relative 
units of Tubedown. 
There was a direct correlation between unfavorable histopathology of neuroblastoma 
specimens and a high level of Tubedown expression. High levels of Tubedown 
expression (1.38+/- 0.08 relative units) were present in the unfavorable tumors whereas 
low levels ofTubedown expression (1.09 +/- 0.07 relative units) were observed in the 
favorable tumors (p=0.009) (Figure 2-3B). High levels of Tubedown (2: 1.3 relative 
units) were observed in 77% of unfavorable neuroblastoma tumors compared to 24% of 
favorable tumors. There was no correlation between the levels ofTubedown expression 
and whether or not the patient was diagnosed at an early age (less than 12 or 18 months 
of age). Tubedown expression did not correlate with MYCN amplification status of 
neuroblastoma tumors. Similarly, the treatment status of the neuroblastic tumors did not 
show significant correlation with Tubedown staining. 
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2.1.5.2 High levels of Tubedown in neuroblastoma tumors correlate with high-
risk and low survival rate 
Classification of our neuroblastoma cohort into three risk groups, low, intermediate and 
high, revealed a significant positive correlation between high Tubedown expression and 
the high-risk neuroblastoma patients (Figure 2-30). Lower levels ofTubedown 
expression (1.00 +/- 0.08 relative units) were detected in the low-risk neuroblastoma 
patients compared to the intermediate- (1.32 +/- 0.12) and high-risk neuroblastoma 
patients ( 1.41 +/- 0.06; p=0.0004). High levels of Tubedown expression (~ 1.3 relative 
units) were observed in 73% of high-risk neuroblastoma cases compared to 21% in low-
risk cases. Kaplan Meier analysis (Kaplan & Meier, 1958) revealed significantly better 
outcomes for patients with low Tubedown expression compared to high expression (3-
year overall survival, p =0.038) (Figure 2-3C). Patients with low Tubedown expression 
had no notable events whereas 46% of patients with high Tubedown expression relapsed 
or died. Moreover, high Tubedown expression (1.50 +/- 0.05 relative units) was found in 
the patients who relapsed or succumbed to the disease (n=8) whereas a low level of 
Tubedown expression (1.01 +/- 0.10 relative units) was observed in patients who 
survived without relapse (n= l4). 
Analysis of our neuroblastoma cohort revealed that the event-free survival rate of patients 
within the cohort depended on the International Neuroblastoma Staging System (stage 4: 
relative risk =6.1), patient's age at diagnosis (greater than or equal to I year: relative risk 
=2.6), undifferentiated status (relative risk =2.5), and MYCN amplification (relative risk 
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= 1.1 ). The relative risk factors for our neuroblastoma cohort were comparable to other 
published cohorts (Krams et al., 2004; Hsu et al. , 2005; London et al., 2005). The 
median age of the patient at diagnosis was 24 months (range: 0.1 to 288 months) and the 
percentage of MYCN amplified tumors was 29%. 
2.1.5.3 Tubedown is down-regulated in neuroblastoma cells undergoing marked 
neuronal differentiation 
Since Tubedown levels in the differentiated neuroblastic tumor subtypes 
(ganglioneuroma and ganglioneuroblastoma with minimal neuroblastic component) are 
low and since the state of neuroblastoma tumor cell differentiation is likely an important 
biological factor for the clinical outcome (Shimada et al., 1999a; Shimada et al. , 1999b), I 
examined Tubedown expression as a function of the differentiation of neuroblastoma cell 
lines in vitro. Tubedown expression was analyzed in neuroblastoma cell lines induced to 
undergo differentiation by treatment with retinoic acid. The extent of neuronal 
differentiation in response to retinoic acid-treatment was first analyzed in 3 neuroblastic 
type neuroblastoma cell lines (LA-N-5, IMR-32 and SK-N-DZ). Upon treatment with 
retinoic acid, LA-N-5 cells developed significantly more neurite-like processes (increased 
length and thickness) than controls (Figure 2-4). Retinoic acid treatment of SK-N-DZ 
and IMR-32 cells did not significantly induce process development compared to controls 
(Figure 2-4). Retinoic acid treatment resulted in 
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Figure 2-4. Morphological differentiation of neuroblastoma cells upon retinoic acid 
treatment. 
LA-N-5, SK-N-DZ, and IMR-32 neuroblastoma eel/lines grown for 3 or 6 days in the 
absence (panels A and C, respectively) or presence ofretinoic acid [RAJ (panels Band 
D, respectively). LA-N-5 cells (panel D) exhibit an increase in the length and the 
thickness of neurites (white arrows) and cellular clustering (black arrows) in response to 
retinoic acid treatment as compared to control (panel C). Representative experiments 
are shown at 400X magnification. 










moderate inhibition of cell growth in LA-N-5 while more significant growth inhibition 
was observed in IMR-32 and SK-N-DZ cells (Figure 2-5). The retinoic acid-induced 
differentiation in LA-N-5 cells was accompanied with a marked up-regulation of 
neurofilament-160 kDa (NF-M) expression (Figure 2-6A). The SK-N-DZ and IMR-32 
cells displayed a modest or no increase in NF-M expression upon retinoic acid treatment 
(Figure 2-6A). All three neuroblastoma lines treated with retinoic acid showed down-
regulation ofvimentin (Figure 2-6B) and c-Myb expression (Figure 2-6C). LA-N-5 and 
IMR-32 lines expressed high levels of MYCN transcript and protein. However, only LA-
N-5 cells significantly down-regulated MYCN transcript (data not shown) and MycN 
protein (Figure 2-6D) expression upon retinoic acid treatment. 
Analysis of Tubedown levels upon retinoic acid-induced differentiation in these 
neuroblastoma cells lines revealed a marked reduction of expression only in LA-N-5 cells 
(Figure 2-6E). The limited retinoic acid-induced differentiation of SK-N-DZ and IMR-
32 cells was associated with a modest or no decrease of Tubedown expression, 
respectively (Figure 2-6E). Real-time RT-PCR analysis of TUBEDOWN transcript 
expression during retinoic acid-induced differentiation of LA-N-5 and IMR-32 cells 
revealed the same pattern of down-regulation observed for the protein expression (data 
not shown). These results indicate that significant reduction in Tubedown expression 
only takes place upon induction of extensive neuronal differentiation in LA-N-5 cells. 
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Figure 2-5. Cell growth of neuroblastoma cells upon retinoic acid-induced 
differentiation. 
6C 6R 
Decreases in viable cell numbers are observed for LA-N-5 (A), SK-N-DZ (B) and!MR-32 
(C) eel/lines when treated with retinoic acid for 3 days (3R) and 6 days (6R) compared 
to 3 (3C) and 6 (6C) days controls. Values are expressed as the mean percentage of the 
control +I- standard error of the mean. Results represent the average of at least three 
experiments. 
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Figure 2-6. Expression dynamics of Tubedown, intermediate filaments, c-Myb and 
MYCN in neuroblastoma cells upon retinoic acid-induced differentiation. 
NF-M [160 kDa (A)}, vimentin [58 kDa (B)] and c-Myb [75 kDa (C)} Western blot 
analyses of untreated(-), 3 days (3) and 6 days (6) retinoic acid (RAJ-treated LA-N-5, 
SK-N-DZ and IMR-32 cell extracts. ERK (44/42 kDa) Western blot analysis was used as 
a loading control. D, MycN (67164 kDa) Western blot analysis of untreated(-), 3 days (3) 
and 6 days (6) retinoic acid (RAJ-treated LA-N-5 and IMR-32 cell extracts. RF/6A cell 
line represents a negative control for MycN expression and ERK Western blot analysis 
was used as a loading control. E, Western blot analysis with Abl 272 anti-Tubedown 
antibody (69 kDa) of untreated (-), 3 days (3) and 6 days (6) retinoic acid (RAJ-treated 
LA-N-5, SK-N-DZ and IMR-32 cell extracts. Tubulin (55 kDa) was used as a loading 
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Tubedown is highly expressed in neuroblastoma cell lines and certain subsets of 
neuroblastic tumors. In normal adrenal tissues Tubedown expression is almost 
undetected. High Tubedown levels are detected in tumors presenting significant 
neuroblastic component and unfavorable histopathology such as advanced stage 
neuroblastoma and some nodular ganglioneuroblastoma. Conversely, low levels were 
detected in low stages neuroblastoma, ganglioneuroblastoma with favorable 
histopathology and ganglioneuroma. High levels of Tubedown expression also correlated 
with high-risk group and significantly reduced overall survival rate. These results 
suggest that Tubedown may be a useful marker for unfavorable neuroblastic 
histopathology of neuroblastic tumors. This may be especially true for the 
ganglioneuroblastoma subsets as a marked difference was observed in the levels of 
expression of Tubedown in ganglioneuroblastoma with favorable versus unfavorable 
histopathology. Tubedown may offer a means to assess the state of differentiation in 
cases of ganglioneuroblastoma, which are difficult to assess. The state of differentiation 
of ganglioneuroblastoma may be critical to clinical outcome of the disease (Joshi, 2000). 
Our results also indicate that Tubedown is a useful marker for neuroblastoma tumors 
within the high-risk group and advanced stages as well as for predicting poor outcome. 
However, since the range ofTubedown expression overlapped to a certain degree in low-
risk versus high-risk patients and in tumors with favorable versus unfavorable 
histological features, the determination ofTubedown levels in neuroblastic tumors may 
be more useful in multivariate analyses with other parameters (age at diagnosis, 
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International Neuroblastoma Staging System, histopathological features, DNA ploidy, 
and MYCN amplification status). 
The more differentiated subset of neuroblastic tumors (ganglioneuroblastoma with 
favorable histopathology and ganglioneuroma) express lower levels of Tubedown. 
However, the differentiation status within neuroblastoma specimens was not associated 
with significant differences in Tubedown expression. Since the International 
Neuroblastoma Pathology Classification system (Shimada et al., 1999a; Shimada et al., 
1999b) categorizes neuroblastoma tumors as differentiating if 5% or more of the cells 
appear differentiated while poorly differentiated if less than 5% of cells appears 
differentiated (Joshi, 2000), a 5% more or less of differentiated cells would not affect the 
overall levels of Tubedown expression within a given specimen. Tubedown levels may 
only be reduced if the tumor specimen presents significant levels of differentiation as 
seen in ganglioneuroblastoma and ganglioneuroma. Moreover, in vitro, reduction in 
Tubedown levels only occurs upon extensive differentiation of neuroblastoma cells. In 
vitro, extensive neuronal differentiation was characterized by Tubedown suppression, 
increases in neurite-like formation and NF-M expression but a marked decrease in MycN 
expression. Reductions in growth, vimentin and c-Myb expression do not appear to be 
sufficient to lead to Tubedown suppression. Our in vitro analyses are in agreement with 
the pattern of expression of Tubedown in neuroblastic tumors and indicate that 
Tubedown expression correlates with the differentiation status of neuroblastic tumors. 
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Tubedown levels did not correlate with MYCN amplification status of neuroblastoma 
tumors. MYCN amplification is a poor prognosis factor that is observed in approximately 
25% of neuroblastoma tumors (Brodeur, 2003). In our neuroblastoma cohort MYCN was 
found amplified in 29% of neuroblastoma tumors while high levels of Tubedown were 
found in 46% of neuroblastoma tumors. The relative risk of our neuroblastoma cohort 
for MYCN amplification was slightly low compared to the cohorts presented by others 
(Krams eta!., 2004; Hsu et al. , 2005). However, it is still clear that within our 
neuroblastoma cohort, amplification of MYCN leads to a higher relative risk compared to 
tumors that are non-MYCN amplified. At least one other factor, the allelic loss of 11 q 
chromosomal locus, was associated with high-risk features (such as advanced stage, older 
age at diagnosis, and unfavorable histopathology) and did not correlate with MYCN 
amplification (Maris, 2005). Both MycN and Tubedown protein expression are reduced 
upon marked retinoic acid-induced differentiation of the LA-N-5 neuroblastoma cell line 
(Figure 2-6). However, although several studies have established a link between MYCN 
RNA and/or protein overexpression and poor outcomes, there is still some controversy 
surrounding this issue (Matthay, 2000; Tang et al. , 2006). 
To date very few markers have been proven to represent an independent prognostic value 
for neuroblastic tumors (Brodeur, 2003 ; Krams et al. , 2004; Maris, 2005). Higher levels 
of Tubed own expression in advanced stage, histologically unfavorable and high-risk 
group neuroblastoma could be the consequence of a more aggressive tumor phenotype or 
could indicate that Tubedown itself somehow drives the aggressiveness of neuroblastic 
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tumors. In vitro, only marked differentiation of neuroblastoma cell lines is associated 
with reduced expression ofTubedown. In primary tumors, lower levels ofTubedown are 
observed in the more differentiated subsets of neuroblastic tumors. These results could 
indicate that Tubedown is involved in blocking differentiation. At present the role of 
Tubedown in aggressive neuroblastic tumors is not clear. However, in yeast the 
Tubedown homologue Natl acts in a complex with the acetyltransferase Ardl to regulate 
a wide range of cellular processes including cell growth and differentiation (Gautschi et 
a!. , 2003; Polevoda and Sherman, 2003 ; Wang et al., 2004). Similarly to the yeast 
system, Tubed own forms a complex with a mouse homolog of the yeast Ard 1 
acetyltransferase (mARDI) (Sugiura eta!., 2003) and has been shown to be involved in 
cellular processes that regulate cell growth and differentiation in different cellular 
contexts (Willis eta!., 2002; Wallet al., 2004; Arnesen eta!., 2006c). 
My results indicate that the levels of Tubedown expression are linked to the 
differentiation status and aggressiveness of neuroblastic tumors. Tubedown 
expression may be useful to more accurately define different neuroblastic tumor 
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3.1.2 Abstract 
Background: Tubedown is a developmentally regulated subunit of theN-terminal 
acety !transferase Ard 1 that is highly expressed in a subset of neuroblastoma tumors. 
High levels of Tubedown expression in neuroblastoma correlate with high risk, low 
survival, and elevated levels of the transcription factor MycN. MYCN amplification 
occurs in approximately 20% of neuroblastomas, associates with poor prognosis and 
usually results in high MYCN expression. In the present study, I further characterized the 
link between Tubedown and MycN expression in neuroblastoma. 
Methods: Patterns of expression of Tubedown, Ard 1, and MycN during neuronal 
differentiation of neuroblastoma cells were analyzed by Western blot. The role of MycN 
on Tubedown and Ard 1 expression was assessed using an inducible MycN expression 
neuroblastoma cell system. Chromatin Immunoprecipitation was used to determine if 
MycN binds to the promoter region of TUBEDOWN. 
Results: I demonstrate a co-regulation between Tubedown, Ard 1, and MycN expression 
during the neuronal differentiation of neuroblastoma cells. Moreover, conditional over-
expression of MycN in neuroblastoma cells increased both Tubedown and Ard 1 
expression. TUBEDOWN promoter region was found to harbour a consensus E-box 
binding motif for MycN. Chromatin immunoprecipitation assays in neuroblastoma cells 
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confirmed that MycN directly binds the 5 '-untranslated I promoter region of 
TUBEDOWN containing this E-box motif. 
Conclusions: The regulation of TUBEDOWN by MycN could play a mechanistic role 
leading to poor outcome for neuroblastoma. Moreover, our work provides further insight 
into understanding the biology of neuroblastic tumors. [In preparation} 
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3.1.3 Background 
Tubedown (Tbdn, also designated NATH, Nargl, hNatl) is associated with an 
acetyltransferase activity and is homologous to the yeast N-terminal acetyltransferase 
subunit Natlp. Tbdn forms a functional acetyltransferase NatA complex with Ard1 
which is conserved from yeast to humans (Park and Szostak, 1992; Sugiura et al., 2003; 
Arnesen et al. , 2005a; Arnesen et al. , 2008). TBDN is transiently expressed during 
embryogenesis in the developing vasculature and diminishes in adult during vascular 
maturity (Gendron et al., 2000). Similarly, a spatia-temporally specific expression 
pattern of TBDN and ARDJ has been reported in neuronal tissue during embryogenesis. 
The expression of both genes decrease throughout brain development and is lowest in 
adult (Sugiura et al., 2003). There is evidence that the Tbdn/Ardl complex is involved in 
a wide range of processes including cellular growth and differentiation (Park and 
Szostak, 1992; Paradis et al. , 2002; Willis et al., 2002; Sugiura et al. , 2003; Arnesen et 
al. , 2005a; Arnesen et al. , 2006b). For example, a decrease in Tbdn levels occur during 
retinoic acid (RA) induced differentiation of neuroblastic tumor cells and mouse 
embryonic carcinoma cells (Sugiura et al., 2003; Martinet al. , 2007). Tbdn and Ard 1 
expression has been shown to be co-regulated and the knockdown of Tbdn in diverse 
cellular systems is associated with a reduction in Ard 1 expression (Sugiura et al. , 2003 ; 
Arnesen et al. , 2006c; Hou et al. , 2007; Paradis et al. , 2008; Polevoda et al., 2008). 
Recently, new nomenclature has been introduced to rename NATJ as NAA 15 and ARDJ 
as NAAJO (Arnesen et al. , 2009). 
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The NatA complex also plays a role in ribogenesis as it binds the nascent polypeptide-
associated complex and associates with ribosomes in yeast (Gautschi et al. , 2003; 
Arnesen et al., 2005a; Raue et al. , 2007; Polevoda et al., 2008). N-terminal acetylation of 
nascent polypeptides by NatA occurs at specific substrate residues (Polevoda et al. , 
2008). A third component of the NatA found at ribosomes is the putative 
acetyltransferase Nat5 , which was described in both yeast and human but has yet to be 
studied at the functional level (Gautschi et al., 2003; Arnesen et al. , 2006a; Arnesen et al. , 
2008). Recently, our laboratory demonstrated that Tbdn is present in a complex with 
Cortactin (Paradis et al., 2008). Cortactin modulates the Actin cytoskeleton, is important 
for a variety of processes including cellular permeability (Mehta and Malik, 2006) and 
has been shown to be involved in tumor progression (Weaver, 2008). 
Tbdn is also involved in tumorigenesis (Arnesen et al., 2006c ). Tbdn is highly expressed 
in aggressive neuroblastoma tumors (Martinet al., 2007), thyroid carcinomas (Fluge et 
al., 2002), and gastric cancer (Line et al. , 2002). Knockdown ofTbdn in tumor cells is 
associated with reduced viability (Arnesen et ·al., 2006c). In neuroblastoma, high levels 
of Tbdn expression have been linked to high-risk and poor outcome (Martin et al., 2007). 
This down-regulation in Tbdn expression is accompanied by suppression of the 
transcription factor MycN (also referred to as N-Myc) (Martinet al., 2007). MYCN is 
amplified in over 20% of neuroblastoma tumors (Brodeur, 2003). MYCN amplification 
usually results in high MycN mRNA and protein expression (Tang et al., 2006). 
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Amplification and over-expression of MycN contributes to neuroblastoma aggressiveness 
and can lead to increased tumor growth and tumorigenicity (Seeger et al., 1985; Weiss et 
al., 1997; Cohn and Tweddle, 2004). The Myc family of proteins ( c-Myc, MycN and L-
Myc) have been considered to have growth-promoting properties (Vita and Henriksson, 
2006). Deregulation of Myc family members such as MycN can result in the 
development of neuroblastoma (Weiss et al., 1997). The Myc family of proteins belongs 
to the basic helix-loop-helix leucine (bHLH)-zipper class of transcription factors 
(Grandori and Eisenman, 1997) that dimerize with other bHLH family members such as 
Max, a ubiquitously expressed transcription factor (Lu et al., 2003). The MycN/Max 
complex recognizes and binds to theE-box motif (CACGTG) with high affinity resulting 
in transcriptional activation of target genes (Vasudevan et al. , 2005). To date, there are a 
limited number of MycN/Max target genes known to be expressed in neuroblastomas 
such as cellular RA binding protein II (CRABP-11) (Gupta et al., 2006), mini-
chromosomal maintenance proteins 2- 7 (MCM2- 7) (Koppen et al., 2007) and multi-
drug resistance-associated protein (MRP1) (Manohar et al., 2004). However, the MycN 
target genes responsible for neuroblastoma tumor progression are still unclear (Manohar 
et al. , 2004). Consequently, the co-regulation ofTbdn and MycN in neuroblastoma cells 
may indicate that Tbdn is involved in a dependent or independent mechanism with 
MycN, which may play a role in regulating cancer growth. Based upon previous data in 
which I found that Tbdn expression was correlated with neuroblastoma risk, I undertook 
the present study to determine if My eN regulates Tbdn expression. My results 
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demonstrate that MycN is regulating both Tbdn and Ard 1 expression. In addition, MycN 
can bind directly to the TBDN promoter region. 
3.1.4 Methods 
Cell Cultures- The LA-N-5 (Seeger et al., 1982b) neuroblastoma cell line was a gift 
from Dr. Thomas Inge (Cincinnati Children's Hospital Medical Center, Cincinnati, OH). 
The neuroblastoma SHEPTet2 (Tet2) and SHEPTet2/Nmyc (Tet2N) cell lines were gifts 
from Dr. Manfred Schwab (German Cancer Research Center, Heidelberg, Germany) and 
have been described previously (Lutz et al., 1996). In brief, the Tet2 cells were generated 
by co-transfection of SHEP cells (a subclone of SK-N-SK human neuroblastoma cells) 
with pUHD15-l containing tTA coding sequence under the control of the human 
cytomegalovirus promoter and a plasmid conferring neomycin resistance. Tet2N cells 
were generated by co-transfection ofTet2 cells with a hygromycin resistance plasmid and 
pUHC 10-3 containing human MYCN coding sequence under the control of seven copies 
of the tet operator and a cytomegalovirus minimal promoter. Upon removal of 
tetracycline, MycN expression is induced in the Tet2N cell line (Lutz et al., 1996). 
The LA-N-5 cells were maintained in RPMI 1640 Media supplemented with 10% heat-
inactivated fetal bovine serum and 2 mM glutamine. The Tet2 cells were maintained in 
RPMI 1640 media supplemented with 10% heat-inactivated fetal bovine serum, 4 mM 
glutamine, and 200 j..tg/ml G418. The Tet2N cells were maintained in the same media as 
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Tet2 with the addition of 90 !J.g/ml hygromycin B. In order to induce MycN suppression 
in the Tet2N cells, tetracycline was added to a final concentration of 1 !J.g/ml. The LA-N-
5 cells were treated with all-trans RA (Sigma, Oakville, Ontario, Canada) to induce 
differentiation at an optimal concentration of 4 !J.M. The culture media with or without 
RA was changed every 3 days. Exponentially growing cells were used for every 
experiment. 
Antibodies - Anti-chicken Ard 1 antibody OH020 was generated by immunizing chickens 
with a KLH-conjugated 11 mer peptide (ENKVESKGNSP) corresponding to the amino 
acids sequence of human Ard 1 positions 177-187 onto which a cysteine residue was 
added at theN-terminus to facilitate coupling (Covance Research Products, Denver, PA). 
Other antibodies used in this study include ARD1 (E-16) (Santa Cruz Bioteclmology, 
Santa Cruz, CA), Max (C-17) (Santa Cruz Biotechnology), N-Myc (C-19) (Santa Cruz 
Biotechnology), MycN(2) [sc:142] (Santa Cruz Biotechnology), Tbdn C755-766 (Paradis 
eta!. , 2008), extracellular signal-regulated kinase (ERK)-1 (K-23) (Santa Cruz 
Biotechnology), alpha-Tubulin (Sigma) and negative control isotype match mouse lgG2a 
(Dako, Glostrup, DK). 
Western Blotting - Celllysates were prepared from cell lines as previously described 
(Gendron eta!., 2000). Protein lysates were quantified using Albumin as standard and 
analyzed by SDS-PAGE. Western blotting was performed using standard procedures as 
previously described (Gendron eta!., 2000; Gendron et al., 2001). Western blot 
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chemiluminescence signal detection varied depending on the antibody used. ECL 
advance (Amersham Biosciences, Piscataway, NJ) was used for detection ofTbdn C755-
766, OH020, ARD1, and N-Myc antibodies; Lumiglo (KPL, Gaithersburg, MD) was 
used for the detection of the Max antibody; and ECL plus chemiluminescence reagent 
(Amersham Biosciences, Piscataway, NJ) was used for the detection of the ERK-1 and 
alpha-Tubulin antibodies. Densitometric analyses were performed using the Kodak Gel 
Logic Imaging System (Eastman Kodak Company, Rochester, NY) with Kodak 
Molecular Imaging Software (Version 4.0, Eastman Kodak Company, Rochester, NY). 
Chromatin Jmmunoprecipilation (ChiP) - ChiP assays were based on modified versions 
of published protocols (Boyd and Farnham, 1999; Strieder and Lutz, 2003) (Farnham 
laboratory, http://genomecenter.ucdavis.edu/farnham/farnham/protocols /chips.html). 
The Tet2N (MycN inducible) cell line was cultured in the presence or absence of I ~Lg/ml 
of tetracycline. Cultures were cross-linked with the addition of formaldehyde to a final 
concentration of 1% for 10 min at room temperature. To terminate the cross-linking 
reaction glycine was added to a final concentration of 125 mM. Cells were washed and 
scraped into cold phosphate-buffered saline, centrifuged, resuspended in swelling buffer 
(5 mM HEPES pH 8.0, 85 mM KCI, 0.5% Nonidet P-40, and protease inhibitors such as 
1 mM Phenylmethanesulfonyl fluoride [PMSF], 0.3 U/ml aprotinin, 10 J.Lg/ml leupeptin) 
and incubated on ice. Cells were next homogenized and centrifuged. The pellets were 
resuspended in sonication buffer (I 0 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDT A, 1% 
Nonidet P-40, 1% deoxycholate, 0.1% SDS, and 500 J.!M PMSF) and incubated on ice. 
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Lysed nuclear extracts were then sonicated at an amplitude of 15% maximum power 
using a Virsonic Cell Disrupter (The Virtis Company, Gardiner, NY) for two I 0 seconds 
pulses on ice to obtain DNA fragments of 500-1000 bp. The chromatin solutions were 
cleared for 10 min. at 1 OOOOXg. Chromatin pre-clearing was performed using pre-
blocked (with 1 J.lg of sheared herring sperm DNA per ml and I J.lg of Bovine Serum 
Albumin per ml for at least 4 hrs at 4°C) protein-G sepharose for 15 min. at 4°C on a 
rotating platform then centrifuged at 1 OOOOXg. Immunoprecipitations were performed 
overnight at 4°C with a mouse monoclonal MycN(2) [sc: 142] or the control isotype 
matched IgG2a. The samples were eluted, reversed cross-linked and Real-time qPCR was 
performed. For each ChiP assay, a standard control was used. A ratio was obtained 
using the standard control with both the MycN immunoprecipitation and the lgG2a 
immunoprecipitation. For each primer pair, the difference in threshold cycle (delta CT) 
was calculated. 
Real-time PCR (qPCR) - DNA was amplified by real-time PCR using a 7000 sequence 
detector system (Applied Biosystems, Foster City, CA). The area of interest included an 
E-box site located within the TBDN promoter region [GenBank: NM057175] with the 
forward primer, 5' -CAAGCTCCGAAACCCAGAG-3 ' (Figure 3:-116 to -98), and the 
reverse primer, 5' -CGTAGCTGCTTCAGCCTTG-3 ' (Figure 3: +161 to +179). The 
positive control contained an E-box sequence located within the MCM2 promoter 
[GenBank: NM004526] with the forward primer, 5' -CTCCGTGTCCCTTCTGGTC-3 ' 
(nucleotide positions from the predicted transcription start site: -91 to -73), and the 
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reverse primer, 5' -GA TCCTCTCCGCCACTACAG-3' (nucleotide positions from the 
predicted transcription start site: +27 to +46) (Koppen et al., 2007). The negative control 
lacked an E-box sequence within the MCMJ 0 promoter region [GenBank: NM182751] 
with the forward primer, 5'-CCTCGCAGGCTTTGTAGATT-3' (nucleotide positions 
from the predicted transcription start site: +728 to +747), and the reverse primer, 5'-
GCCACGGTAATCTTCCCTTT-3' (nucleotide positions from the predicted transcription 
start site: +833 to +852) (Koppen et al. , 2007). 
Sequence Analysis ofTBDN 5 '-Untranslated region (UTR) I Promoter - The 
transcriptional start site for the TBDN gene was determined using the Database of 
Transcriptional Start Sites (DBTSS) (http://dbtss.hgc.jp) in combination with the NCBI 
database (http://www.ncbi.nlm.gov/sites/entrez?db=pubmed). The transcriptional start 
site and 5' -UTR for TBDN was located on chromosome 4 (GenBank: NM_057175) using 
the Entrez Gene component ofthe NCBI database. Examination ofthe 5' -UTR / 
promoter region was completed using manual scanning, along with, the Transcription 
Element Search System (TESS) software (http://www.cbil.upenn.edu/cgi-bin/tess/tess) 





Tbdn and Ardl are co-regulated with MycN in neuroblastoma cells 
undergoing marked neuronal differentiation 
To assess patterns of expression of Tbdn, Ard 1, MycN and MycN binding partner Max 
during differentiation of neuroblastoma cells, levels of these three proteins were co-
examined upon RA-induced differentiation ofLA-N-5 cells by Western blot analyses 
(Figure 3-1 ). Tbdn expression was down-regulated upon RA-induced differentiation of 
LA-N-5 cells with a 2.1 -fold decrease at day 3 (Figure 3-1 ). Similarly, RA-induced 
differentiation in LA-N-5 cells was accompanied by a marked down-regulation of Ard I 
protein expression with a 4.2-fold decrease at day 3 (Figure 3-1). MycN expression was 
decreased by 5-fold upon 3 days ofRA treatment of human neuroblastoma LA-N-5 cells. 
On the other hand, the level of Max, a transcriptional binding partner of MycN, was 
decreased by 1-fold compared to untreated cells following 3 days ofRA treatment ofLA-
N-5 neuroblastoma cells (Figure 3-1 ). 
3.1.5.2 Conditional MycN over-expression leads to up-regulation of Tbdn and 
Ardl 
To further investigate the relationship between MycN and Tbdn!Ardl , a conditional 
MycN expression system (Lutz et a!. , I 996) was used to determine the effect of MycN 










Figure 3-1. Tbdn co-regulation with MycNIArdl during cell differentiation. 
Western blot analyses of untreated (-) and 3 days of RA -treated human neuroblastoma 
LA -N-5 cells was performed RA treatment of LA -N-5 cells induces a significant 
decrease in the levels of Tbdn (101 kDa), Ard1 {28 kDa), and MycN (67 kDa) expression 
whereas only a minimal change in Max (21120 kDa) expression was detected. ERK1/2 
( 44/42 kDa) Western blot analysis was used as a loading control. The results are from 
representative experiments. 
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these analyses I used a MycN inducible cell line (Tet2N) previously derived by Lutz et al. 
( 1996) based on the SHEP neuroblastoma cell line (as it lacks endogenous My eN 
expression). In the Tet2N cells MycN expression is suppressed upon tetracycline 
treatment (Figure 3-2; Lutz et al., 1996). The conditional over-expression of MycN is 
accomplished in the absence of tetracycline by the induction of a MYCN eDNA construct 
under the control of the tetracycline responsive element (TRE) and the tetracycline-
regulated transactivator (tTA) (Lutz et al. , 1996; Zhu eta\. , 2002). Western blot analyses 
showed that removal of tetracycline from the Tet2N cell line resulted in an over-
expression of MycN (Figure 3-2) as previously described (Lutz et al. , 1996). The Tet2 
(empty vector) cells did not express MycN upon removal of tetracycline. Parallel 
Western blot analyses showed that Tbdn was up-regulated 2.2-fold and Ard1 was up-
regulated I. 7-fold after tetracycline withdrawal from Tet2N cell line but not from Tet2 
control cells (Figure 3-2). 
3.1.5.3 MycN binds a TBDN promoter region 
Based on the co-regulation of Tbdn and Ard 1 with MycN and the up-regulation of Tbdn 
and Ard 1 upon conditional over-expression of MycN, the genomic sequence of TBDN 
promoter region was examined for a Myc-responsive element, an E-box binding motif 
An E-box binding motif was located within the 5'-UTR I promoter region of TBDN. 
Figure 3-3 illustrates that theE-box motif is located after the transcriptional start site (at 
position+ 12) within the beginning of the 5' -UTR of TBDNtranscript. The TBDN 
promoter appears to be aT AT A-less promoter similar to the MYCN promoter (Inge et al. , 
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2002). In addition, the TBDN promoter is GC rich and includes a GC-box element at 
position -177 to -172 (Figure 3-3) which is known to bind SP 1. SP 1 is a transcription 
factor involved in early development, binding sites for which are also seen within the 
MYCN promoter region (Inge et a!., 2002). The TBDN promoter also contains three 
Hypoxia responsive elements (HRE) harboring the consensus sequences 5'-(A/G)CGTG-
3'. Two of these HRE motifs are found within the promoter region while a third motif 
overlaps with theE-box motif located within the 5' -UTR (Figure 3-3). To determine if 
MycN binds the 5' -UTR and promoter region of TBDN encompassing the Myc-
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Figure 3-2. MycN over-expression induces Tbdn and Ardl expression. 
(A) Western blot analyses revealed that removal of tetracycline from the in vitro MYCN-
inducible expression system, Tet2N, resulted in an over-expression of MycN and an up-
regulation of Tbdn and Ardl expression. Graphical representation of Tbdn (B) and Ardl 
(C) levels are shown. Each Western blot is paired with the respective loading control 
Tubulin or ERK. Results represent the average of at least three experiments. The results 
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Figure 3-3. The nucleotide sequence of TBDN promoter region contains a canonical 
E-box motif. 
The illustration depicts the nucleotide sequence ofTBDN promoter region and TBDN 
transcript [GenBank: NM05 717 5}. The nucleotide sequence contains 52 2 bp of the 
proximal promoter, 256 bp of the 5 '-UTR and 142 bp of the coding sequence (CDS). 
Binding sites for known transcription factors are highlighted in gray whereas the forward 
(F) and reverse (R) primers are underlined. 
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responsive element (E-box) a ChiP assay was performed. The Tet2N cell line (which 
expressed MycN in the absence of tetracycline) was used to analyze the TBDN 5' -UTR 
and promoter region. Throughout the ChiP procedure various confirmatory steps were 
required. The cells were monitored under the microscope during the addition of the 
swelling buffer and during the lysis of the nuclei. In addition, samples from the 
sonication step were verified on a gel to ensure correct fragment size (500 - 1000 bp). 
Quantitative Real-time PCR (qPCR) was then performed on DNA immunoprecipitated 
with either an anti-MycN antibody or an anti-IgG2a negative isotype matched control 
antibody. The variation in threshold cycle (delta CT) of the qPCR was determined for 
each san1ple. qPCR using TBDN primers flanking the E-box motif in TBDN 5' -UTR I 
promoter region and ChiP DNA revealed approximately a 6-fold increase in the delta CT 
of MycN-ChiP over IgG2a-ChiP (Figure 3-4). MCM2 primers flanking an E-box motif in 
MCM2 promoter (positive control promoter region regulated by MycN; Koppen eta!., 
2007) region showed approximately an 8-fold increase in the delta CT between the 
MycN-ChiP samples and the negative control IgG23-ChiP (Figure 3-4). MCMJO primers 
flanking a region in MCMJ 0 promoter devoid of an E-box (negative control promoter 
region not regulated by MycN; Koppen eta!., 2007) presented no increase in the delta CT 
between the MycN-ChiP samples and the IgG2a-ChiP (Figure 3-4). The qPCR products 
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Figure 3-4. MycN binds to the TBDN promoter. 
Delta Ct of qPCR on ChiP analysis of MycN binding to theE-box motif region in the 
MCM2 (black bar) or 1BDN (gray bar) promoter and absence of binding of MycN to 




Previously, I showed that high levels ofTbdn expression are linked with aggressive and 
high-risk group neuroblastoma and are associated with poor survival (Martinet al. , 
2007). The aggressiveness of neuroblastoma has also been linked to MYCN amplification 
(Thiele eta!. , 1985; Wei et al. , 2008) but the reason for such an association is still unclear 
(Brodeur, 2003). MYCN amplification is associated with poor prognosis in 
neuroblastoma patients (Pession and Tonelli, 2005). There is a correlation between 
MYCN-amplified neuroblastoma tumors and MycN expression (Tang et al., 2006). Over-
expression of human MycN under the control of a tyrosine hydroxlyase promoter in a 
transgenic mouse model leads to the development of neuroblastoma (Weiss et al. , 1997). 
It is also worth mentioning that there was a co-regulation between Tbdn and MycN upon 
RA-induced differentiation of neuroblastoma cells (Martin et al. , 2007). Based upon 
these findings, I sought to determine here if Tbdn expression and MycN are in any way 
functionally linked. 
In this report, I demonstrate that Tbdn and Ard 1 protein expression correlate with MycN 
expression during RA-induced differentiation of neuroblastoma cells. Our group as well 
as others have reported a significant down-regulation of MycN expression upon RA 
treatment of neuroblastoma cells (Thiele et al., 1985; Martinet al. , 2007). In addition a 
significant down-regulation of both Tbdn and Ard1 expression accompanied this RA-
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induced differentiation. Although MycN heterodimerizes with Max to activate 
transcription, I have observed only a moderate decrease in Max expression upon RA-
induced differentiation. Nevertheless, our results are in agreement with Cetinkaya et al. 
(2007) who demonstrated a modest reduction in Max expression upon RA-induced LA-
N-5 cells (Cetinkaya et al., 2007). To verify my results, additional neuroblastoma cell 
line with and without MYCN amplification would be required. 
The well-established MycN-induced SHEP model (Lutz eta!., 1996) has been widely 
used to investigate a number of target genes in neuroblastoma (Manohar et al. , 2004; 
Slack et al. , 2005; Gupta et al. , 2006; Koppen et al. , 2007; Dasgupta et al., 2009). The 
MycN-inducible model was used to study the effects of both Tbdn and Ard I in 
neuroblastoma cells. The parental SHEP cell line is an epithelial-like cell line (S-type) 
and not a neuronal derived cell line (N-type) (Ross et al., 1983). The SHEP cell line was 
used by Lutz and colleagues because it lacked MYCN amplification and MYCN 
expression. My results show an increase in Tbdn and Ard 1 protein expression upon 
conditional over-expression of MycN in neuroblastoma cells. These observations 
indicate that MycN regulates Tbdn and Ard1 expression in neuroblastoma. In addition, 
our previous data demonstrated a correlation between MycN, Tbdn, and neuroblastoma 
differentiation status (Martinet al. , 2007). To verify my MYCN-inducible data, an 
alternative approach targeting the knockdown of MYCN through siRNA or antisense 
teclmology could have been used. 
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To further explore if the regulation of Tbdn expression by MycN was direct or indirect, 
the promoter I 5' -UTR region of TBDN was examined for potential MycN binding sites. 
The identification of a MycN canonical E-box motif, CACGTG, within the TBDN 
promoter I 5'-UTR region suggests that MycN could potentially regulate Tbdn expression 
directly through up-regulation of transcription. Conversely, no canonical E-box motif 
could be identified within the ARDJ promoter region for MycN to bind and regulate 
ARDJ expression. It is possible that MycN regulates Ardl expression indirectly through 
the action of another transcription factor. Alternatively, Tbdn levels have been shown to 
regulate Ardl in systems other than neuroblastoma such as thyroid carcinoma (Arnesen et 
al. , 2005b), cervix adenocarcinoma HeLa cells (Arnesen et al., 2006c), and endothelial 
cells (Paradis et al. , 2008). Therefore, Tbdn up-regulation itself could be responsible for 
the up-regulation of Ard 1 in neuroblastoma. However, the mechanism for such 
regulation remains to be elucidated. 
Our results further show that MycN binds to the promoter I 5' -UTR region of TBDN that 
contains the identified canonical E-box motif. These results suggest that MycN directly 
regulates Tbdn expression through regulation of gene expression. It is not uncommon for 
E-box elements to be located within the 5' -UTR. Miltenberger et al. (1995) mapped an 
E-box motif to the 5' -UTR of Cad which was responsible for growth-dependent 
transcription of this gene (Miltenberger et al. , 1995). Similarly, Hayama et al. (2007) 
reported the presence of an E-box motif within the 5' -UTR of Polyserase-1 as a required 
element for maximal promoter activity (Hayama et al. , 2007). 
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An E-box motif within the promoter I 5'-UTR of TBDN indicate a potential binding site 
for not only Myc/Max heterodimer but as well as other factors such as Max homodimer, 
Max/Mad heterodimer, Max/Mnt heterodimer, and USF and TFE3 (Facchini and Penn, 
1998; Vasudevan et al., 2005). In addition to having a canonical coreE-box binding 
motif, other characteristics may determine which factor is capable of binding to this site. 
Previous studies have shown that nucleotides flanking theE-box motif determine the 
most likely factor to bind the consensus sequence. Halazonetis & Kandil (1991) tested a 
number of oligonucleotides varying the sequences flanking theE-box and reported that 
the sequence with the highest affinity for Myc/Max was GAC-CACGTG-GTC 
(Halazonetis and Kandil , 1991). However, the flanking 5' nucleotides sequence T(-3)A(-
2)C( -1) also provided an increase in the affinity of the tested promoter region for the 
Myc/Max heterodimer. The numbers represent the position of the nucleotide from the 
flanking core sequence. For exan1ple, -1 at the 5' (or + 1 at the 3 ') would represent the 
position closest to the core sequence whereas -3 (or +3) would be located 3 positions 
from the core sequence. A previous study suggested that purines in either the -2 or the -3 
positions are favored whereas nucleotides such as 5 ' -Tat position -1 (or 3 ' -A at position 
+ 1) would not be preferred residues for Myc/Max (Solomon et al., 1993). However, 
Swanson and Yang ( 1999) demonstrated that there can be some variations in the 5' and 
3' flanking sequences. In particular, the 5'-A/C/T and 3'-G/A/T can be found in the -1 
and + 1 positions, respectively (Swanson and Yang, 1999). The Myc/Max consensus 
binding sequence has been defined as 5' - RHCACGTGDY-3' (Swanson and Yang, 
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1999). The nucleotides flanking the high affinity E-box motif in TBDN consist ofT AC 
in the 5' region whereas the nucleotides in the 3 '- region consist of AAC. These 
nucleotide arrangements would indicate a preferred target for MyciMax in the TBDN 
promoter I 5 ' -UTR region. 
The aforementioned criteria are important in determining potential transcription factor 
binding sites. However, the primary criterion for determining the ability of a 
transcription factor to bind directly to a gene is the actual binding of the factor to the 
regulatory DNA element in the chromatin in situ (Fernandez et al., 2003). One approach 
to assess transcription factor binding sites is the ChlP assay, which can be performed in 
live cells (Fernandez et al., 2003). Using ChlP methodology, I show here that MycN 
binds to the TBDN promoter I 5' -UTR region encompassing the high affinity E-box 
motif. It is well known that Tet2N cells can be induced to express MycN upon 
withdrawal of tetracycline. However, in the presence of tetracycline MycN expression is 
suppressed in Tet2N cells to a minimum (Figure 2A). Lutz et al. ( 1996) showed that 
MYCN expression is not completely repressed in Tet2N cells in the presence of 
tetracycline (Lutz et al., 1996). Accordingly, MycN specific ChiP assays performed on 
tetracycline treated Tet2N cells showed very minimal binding of MycN to the TBDN 
promoter -5'UTR region encompassing theE-box with less than 1-fold delta CT (data not 
shown). 
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Members ofthe Myc family of transcription factors have been linked to many important 
cellular processes including proliferation which is known to provide a growth advantage 
to breast cancer cells, small cell lung carcinomas, and neuroblastoma cells (Ben-Yosef et 
a!., 1998). Conditional over-expression of MycN in Tet2N cells has been associated with 
an increase in cell growth (Lutz et al., 1996; Koppen et al., 2007). In this report, I show 
that the conditional over-expression of MycN in Tet2N cells is accompanied by an 
increase in Tbdn and Ard 1. Moreover, in neuroblastoma cells I previously showed that 
reduced Tbdn expression is accompanied with a decrease in cell growth and increased 
differentiation (Martin et a!., 2007). Arnesen and colleagues (2006) reported that the 
knockdown ofTbdn expression in epithelial cervical adenocarcinoma (HeLa) cells using 
siRNA results in apoptosis (Arnesen eta!., 2006c). Ard1 has also previously been shown 
to play a role in cellular viability (Fisher et al., 2005; Arnesen eta!., 2006c; Lim eta!., 
2006; Arnesen eta!., 2008). It is worth mentioning that cervical carcinoma cells such as 
HeLa cells have been shown to over-express c-Myc (Macville eta!., 1999; Henriksson et 
a!., 200 I). Based on these observations it is temping to speculate a relationship between 
Tbdn and Myc family of transcription factors in other models as well as neuroblastoma. 
These studies collectively suggest that Tbdn may play a role in the growth of cancers. 
A possible explanation for the association of Tbdn and MycN with a growth advantage 
for cancer cells may be based on ribosome biogenesis. Boon and co-workers (200 1) 
demonstrated that MycN enhanced the expression of a large group of genes involved in 
ribogenesis supporting a role for MycN in ribosome biogenesis and in protein synthesis 
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(Boon et al., 2001 ). Gautschi et al. (2003) reported in yeast that the Tbdn orthologue 
Natlp, is required to anchor Ardlp and Nat5p to the ribosome, and interacts with the 
nascent polypeptide-associated complex (Gautschi et al., 2003). Arnesen et al. (2005) 
demonstrated the association of Tbdn and Ard 1 with ribosomal subunits (Arnesen et al. , 
2005a). It is well known that the ribosome is essential for cell growth. However, 
deregulation of ribogenesis can lead to oncogenic transformation (Bilanges and Stokoe, 
2007). One example of the link between deregulation of a product of ribogenesis and 
oncogenesis is the ribosomal protein RPL35a. RPL35a has anti-apoptotic activity and 
has been shown to be over-expressed in glioblastoma, a type of malignant brain tumor 
that has high resistance to chemotherapy (Lindstrom, 2009). Whether the links between 
Tbdn and MycN impact upon ribosome biogenesis or are in any way responsible for 




The work herein demonstrates a co-regulation between Tubedown, Ard 1, and MycN 
expression during the neuronal differentiation of neuroblastoma cells. In addition, I 
demonstrate an increase in Tubedown and Ardl expression upon conditional over-
expression of MycN in an inducible neuroblastoma cellular system. Finally, I show that 
MycN binds to the TBDN promoter. Collectively, these results suggest a new role for 
MycN in regulating Tbdn expression. 
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3.1.8 List of abbreviations 
Tbdn (NATH and Nargl), Tubedown; RA retinoic acid; PMSF, Phenylmethanesulfonyl 
fluoride; UTR, untranslated region; CRABP-11, cellular retinoic acid binding protein II; 
MCM 2 - 7, mini-chromosomal maintenance proteins 2 - 7; MRPl, multi-drug resistant 
protein; Tet2, SHEPTet2; Tet2N, SHEPTet2/Nmyc; ChiP, Chromatin 
Irnmunoprecipitation; qPCR, Quantitative PCR; DBTSS, Database of Transcriptional 
Start Sites; T SS, Transcription Element Search System; HRE, Hypoxia responsive 
elements; Hif, Hypoxia-induced transcription factor. 
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4.1 Suppression of Tubedown Expression 
4.1.1 Introduction 
RA treatment of neuroblastoma cells lead to a more differentiated phenotype associated 
with reduced cell growth in vitro (Sidell et al., 1983). My previous data demonstrated 
that RA treatment of human neuroblastoma LA-N-5 cells induced differentiation and 
resulted in a decrease in Tbdn expression (Martinet al., 2007). In addition, Arnesen and 
colleagues showed that knocking down Tbdn levels in human cervical (HeLa) cells 
resulted in reduced cell viability (Arnesen et al., 2006c). Therefore, the functional 
importance ofTbdn had to be investigated in neuroblastoma cells. In particular, 
suppressing Tbdn levels may play a role in inhibiting growth and/or promoting 
differentiation in neuroblastoma cells. 
4.1.2 Materials and Methods 
Cell culture - LA-N-5 (Seeger et al. , 1982a) cells were a gift from Dr. Thomas Inge 
(Cincinnati Children's Hospital Medical Center, Cincinnati, OH). The LA-N-5 cells were 
maintained in RPMI 1640 media and supplemented with 10% heat-inactivated fetal 
bovine serum and 2 mM glutamine. For all transfection experiments, LA-N-5 cells were 
passaged one day before and grown to 80% confluency. 
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siRNA - Three hundred to 1 000 nM of gene-specific siRNA (Dharmacon, Lafayette CO 
USA) were used for each nucleofection. The following siRNA duplex target sequences 
were used: HS-TBDN611 (positive control): 5'- GGGACCUUUCCUUACUACA-3 ' 
(Arnesen et al., 2006c); SC47 (negative scramble control): 5'-
GAUCCGUUCAUCGUCACUA-3'; HS-TBDN1138: 5'-
GAAGGCUGCCGUUAAACUU-3 . 
Nucleofection - Nucleofections were completed according to the suppli r's adherent cell 
line manual (Amaxa, Cologne, Germany). In brief, LA-N-5 cells were washed with 
sterile phosphate-buffered saline, trypsinized and counted to determine cell density. The 
cells were centrifuged at room temperature for 10 min at 90 g. Following media 
aspiration, the cell pellet was resuspended in 100 ul of nucleofector solution V ( 4.5U) 
containing the supplement solution ( 1 U). The final concentration of the samples were 
4X106 cells/100 ul and 1X106 cells/100 ul. One thousand nanomolar siRNA and 2 ug 
pmax Green Fluorescent Protein (GFP; for monitoring cell transfection efficiencies) were 
added directly to the cell suspension (100 ul /cuvette). The nucleofector device was set to 
program V -00 l or U-0 14. Post nucleofection, the cells were returned to the humidified 
37°C I 5% C02 incubator. 
Microinjection - The Femtoject (Eppendorf, Mississauga, ON, Canada) and lnjectMan 
NI 2 (Eppendorf) were used to inject affinity purified anti-Tbdn rabbit antibody C1 0-20 
(Paradis et al. , 2008) into LA-N-5 cells. Prior to experiment, a tracer such as GFP (100 
1 18 
ug/ml) or Hoechst (0.15 ug/ml) were mixed with the Tbdn antibody and loaded directly 
into the Femtotip. Subsequently, LA-N-5 cells were monitored using a Leica DMIRE2 
microscope system. 
Liposorne-mediated transfection - Liposome transfections were completed according to 
the supplier's manual (Invitrogen, Burlington, ON, Canada). First, the host cell line, LA-
N-5, was incubated with 10 ug regulatory plasmid (pTet-on) and 0.5 - 5 ul of 
lipofectamine (or lipofectin) per ug of DNA. After 48 hrs, 100 ug/ml of G418 was added 
to each plate. G418-resistant clones were selected and analyzed by Northern blot to 
determine which clone had the highest fold-induction (i.e. highest expression with the 
lowest amount of background). Secondly, the response plasmid (pTRE-ASTBDN) was 
co-transfected with a selection agent (pTK-Hyg) at a ratio of 10:1 or 20:1. For every I ug 
of DNA, 0.5 - 5 ul of lipofectamine (or lipofectin) was added. The mixture was placed at 
room temperature for 20 min before adding to the LA-N-5 cells. After 48 hrs, 50 ug/ml 
of hygromycin B (HygroB) was added to each plate. HygroB-resistant and G418-
resistant clones were selected and analyzed by Southern blot for the presence of the 
pTRE-ASTBDN construct and then by Northern and Western blot to determine if the 
levels of Tbdn have been diminished. 
Adenofection - LA-N-5 and Ewing' s sarcoma cells were infected with adenovirus at 
varying levels of MOl (7.5, 10, 12.5). The recombinant adenoviral vector transducing 
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ASTBDN-1 under the control of the CMV promoter (Ad5-CMV I ASTBDN-1) was 
compared to the control vector transducing p-galactosidase (Ad5-CMV /Lac Z). 
4.1.3 Results & Discussion 
Our laboratory was interested in understanding the function of the TBDN gene. 
Therefore, several transfection approaches were carried out to knockdown Tbdn 
expression. Transfection is the process of introducing foreign DNA into eukaryotic cells. 
Methods of transfection can range from viral-based (e.g. adenofection) to physical (e.g. 
microinjection, electroporation) to chemical (e.g. liposome-mediated). 
Adenofection teclmology was originally evaluated in an attempt to knockdown Tbdn 
expression. However, I experienced problems infecting our P-Galactosidase plasmid 
(pcmv P-Gal) into neuroblastoma cell lines. I did not experience any problems with our 
control (Ewing's sarcoma) cell line. After several condition changes, I concluded that 
this technique was ineffective for infecting neuroblastoma cells. Similarly, Skog and 
colleagues also experienced difficulty and could not effectively infect neuroblastoma cell 
lines with adenofection due to a low binding capacity (Skog et al. , 2002). 
The microinjection approach was used to block the activity of the Tbdn protein by 
injecting a Tbdn antibody into the cell. The Femtojet system was used to inject the 
antibody. The major technical issue with this approach was the limited number of cells 
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that could be injected in a short period. In addition, this technique is more effective when 
utilizing flat cells. Unfortunately, LA-N-5 cells tend to grow as clumps adding to the 
difficulty of the injections. Consequently, constant resetting ofthe stage to a new plane 
of focus had to be completed. As a result, this method of injection also proved 
ineffective for our purposes. 
The liposome method of transfection is one of the most commonly used techniques. The 
antisense approach was utilized because it is a well-established way of interfering with 
the expression of the endogenous sense gene. Various transfection reagents such as 
lipofectamine and lipofectin were used to transfect the antisense Tbdn (ASTBDN) eDNA 
into human LA-N-5 neuroblastoma cells. The ASTDBN construct was under the control 
of a tetracycline responsive element (TRE) and reverse tetracycline regulated 
transactivator (rtT A) (Figure 4-1 ). A few caveats with this system and model included a 
very low efficiency rate and very slow growing clones. In addition, the non-induced 
ASTBDN cell line appeared to be deregulated or leaky and was no longer modulated by 
rtT A activation. 
During the initial Southern blot screen of 30 derived LA-N-5/rtT A/TRE-ASTBDN 
clones, three clones (L T AS#8, L T AS# I 0, L T AS# 17) had incorporated the pTRE-
ASTBDN construct. Western blot analysis revealed that clone L TAS#8 showed no 
suppression of Tbdn expression in response to Doxycycline treatment whereas clone 








Figure 4-1. 'Tet-on' inducible antisense Tbdn system. 
rtTA binds to the teto sequence of the let-responsive element (TRE), which controls the 
ASTBDN-1 gene thereby activating transcription in the presence of an inducing agent, 
Doxycycline. ASTBDN-1 eDNA interferes with the expression of the endogenous sense 
Tbdn-1 thereby decreasing Tbdn-1 levels. 
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decreased with and without Doxycycline treatment indicating that the TRE-ASTBDN 
construct in this clone is deregulated (Figure 4-2). Upon further analysis, clone 
L T AS# 15 (which did not contain the pTRE-ASTBDN construct) also displayed similar 
cell cycle results as clones L T AS#8, 10 and 17 indicating that Tbdn is likely not 
regulated by the inducible tetracycline-based system (data not shown). 
The next transfection approach evaluated was nucleofection. I utilized nucleofection 
technology from Amaxa to introduce siRNA Tbdn oligonucleotides into LA-N-5 cells 
with the expectation of silencing Tbdn expression. Nucleofection technology is based on 
electroporation properties in that voltage is used to introduce a substance into a cell 
(Hagemann et al., 2006). This method was very effective in delivering siRNA to LA-N-5 
neuroblastoma cells. Nucleofection technology is based on electrical parameters, as well 
as cell type specific nucleofector solutions. These solutions differed in their buffer 
capacity, ionic strength, and composition. A major disadvantage of this technology is 
that Amaxa holds the electrical parameters and nucleofector solutions in strict confidence 
(Hagemann et al., 2006). Another disadvantage is that every cell line has to be 
optimized. Amaxa has generated a database which contains optimized conditions for 
many commonly used cell lines. Unfortunately, optimized conditions were not available 
for the LA-N-5 cells. I determined that solution V along with nucleofector programs V-
001 and U-014 provided optimal nucleofection rates for the LA-N-5 neuroblastoma cell 
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Figure 4-2. Doxycycline effects on antisense Tbdn clones. 
Western blot analysis of Tbdn-1 (69 kDa) expression with and without Doxycycline. 
Parental (LA-N-5), rtTA (LA-N-5 1ET4, empty vector) and rtTNTRE-ASTBDN 
represents the LTAS#8, 10, 17 clones. ERK (44/42 kDa) represents the loading control. 
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fluorescence protein also known as maxGFP (Figure 4-3). After extensive design, the 
optimal Tbdn siRNA was selected. Levels ofTbdn expression were then assessed by 
Western blot analysis. Unfortunately, I was unable to produce a significant knockdown 
ofTbdn expression. In theory, designing the optimal siRNA is a relatively simple 
process. Design an siRNA of approximately 21 nucleotides that is complementary to 
your sequence of interest to get the desired degraded mRNA. However, in practicality, a 
far better strategy would be to design and test at least ten siRNAs. The next step should 
be to continue testing potential Tbdn siRNAs since an effective transfection approach 
(nucleofection) was found. 
Several transfection approaches were utilized in determining the functional importance of 
Tbdn in neuroblastoma cells. However, due to the many technical problems, I was 
unable to knockdown Tbdn expression in the neuroblastoma cells. Nevertheless, initial 
studies suggested that the nucleofection approach would be an effective method to 
transfect human LA-N-5 neuroblastoma cells. Furthermore, suppressing Tbdn levels will 
determine the importance of Tbdn with respect to growth and differentiation in 
neuroblastoma cells. 
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Figure 4-3. Nucleofection of LA-N-5 cells. 
LA-N-5 cells were transjectedwith maxGFP using the U-014 (A & B) and the V-001 (C 
& D) Amaxa programs. Panels A & C were analyzed by phase-contrast microscopy 
whereas panels B & D were analyzed by immunojluorescene in which the observed green 
fluorescence was due to GFP expression. Magnification, x400. 
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5.1 Summary 
5.1.1 Martinet a/., 2007 
Immunohistochemistry was performed on tissue microarrays, snap-frozen tissues and 
other paraffin-embedded sections using a Tbdn mouse monoclonal OE5 antibody. My 
data demonstrated that Tbdn expression maybe a novel factor that enhances the 
stratification ofNT risk groups. Additionally, Dr. Arie Perry performed the fluorescence 
in situ hybridization experiment to show MYCN amplification (tumors containing more 
than 5 extra copies of the MYCN gene) or MYCN gains (tumors containing 1-4 extra 
copies of the MYCN gene). Corroboration of the results did not reveal any correlation 
between Tbdn expression and MYCN amplification (Martin et al. , 2007). However, a 
potential correlation between Tbdn and MycN protein expression may still exist 
according to my in vitro data. MycN immunohistochemistry experiments were 
completed on paraffin-embedded section. However, a definitive conclusion could not be 
reached by immunohistochemistry because antibodies available for the MycN protein 
were not specific enough. 
In addition to MycN, Tbdn expression was also compared and correlated with the 
differentiation status ofNTs. High levels ofTbdn expression were found in the less 
differentiated NTs (such as the neuroblastomas) whereas low levels ofTbdn expression 
were present in the more differentiated NTs (such as the ganglioneuromas). Previously, 
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in vitro data showed that Tbdn expression correlated with a subset of differentiated 
neuroblastoma cells (Figure 2-6). Morphological changes in a neuroblastoma cell line 
treated with RA led to a decrease in Tbdn expression where the majority of the cells are 
undergoing differentiation upon RA treatment. The differentiated neuroblastoma cells 
had less Tbdn expression compared to the non-differentiated neuroblastoma cells. Based 
on the aforementioned in vitro data, Tbdn expression was compared to the differentiated 
status of the neuroblastoma specimens. Unfortunately, the differentiation status within 
the neuroblastoma specimens from the tissue array did not correlate with Tbdn 
expression. The reason for the discrepancy, as alluded to in chapter 2, was that the INPC 
system considers neuroblastoma specimens as differentiated if 5% or more of the tumor 
contains differentiated cells. However, a population with 5% or less of differentiated 
cells may not affect the overall expression levels of Tbdn for a specific specimen. In 
other words, 5% of the neuroblastoma tumor specimen had to be differentiated for it to be 
classified within the differentiated category. 
Clinically, the more differentiated a tumor, the greater the chance of a response to 
treatment. RA treatment of acute promyelocytic leukemia has been shown to induce 
terminal differentiation of malignant myeloid cells into mature neutrophils (Soignet et a!. , 
1998). Similarly, RA-induced differentiation can affect malignant neuroblastoma cells 
by mimicking the differentiation of neurons in culture (Robson and Sidell, 1985). In 
vitro, different forms of RA have been shown to induce differentiation and decrease the 
growth of neuroblastoma cells (Sidell et al., 1983; Thiele eta!., 1985; Reynolds eta!., 
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1994; Brodeur, 2003). Currently, 13-cis RA is being used in clinical trials with high-risk 
neuroblastoma patients (Matthay et a!., 1999) and is becoming standard practice in the 
treatment of high-risk neuroblastoma (Brodeur, 2003). 
As stated, Tbdn is involved in neuroblastic differentiation, suggesting that it maybe an 
attractive target for cancer treatment. However, according to Arnesen eta!., Tbdn would 
not be useful as a cancer drug target, since decreasing Tbdn would lead to an increase in 
capillary formation (Arnesen eta!., 2008). This statement by Arnesen eta!. was likely 
based on previous data by our group, showing that a down-regulation of Tbdn in an 
endothelial cell model resulted in an accumulation of capillary-like structures (Paradis et 
a!. , 2002). Firstly, I did not observe or report any Tbdn staining of the blood vessels 
within the neuroblastic specimens analyzed. As stated in chapter 2, Tbdn staining was 
not detected in blood cells or vessels (see Figure 2-2C). Secondly, I was looking at Tbdn 
in a different model system than was reported previously. There is a strong possibility 
that Tbdn may have different roles depending on its cellular context. For example, Stat3 
activation is associated with proliferation and promoting apoptosis (Bromberg and 
Darnell , 2000). Activated Stat3 prevents apoptosis and increases proliferation in head 
and neck squamous cell carcinoma. Conversely, Stat3 activation increases mammary 
epithelial apoptosis (Chapman et a!., 1999; Leeman eta!., 2006). Additionally, the 
expression of the nm23-Hl gene can vary with tumor type. High expression of nm23-H 1 
is associated with a favorable outcome in breast cancer and malignant melanomas 
(Hennessy eta!. , 1991 ; Florenes et a!., 1992). Conversely, an up-regulation ofnm23-H1 
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is linked to poor outcome in neuroblastoma and non-Hodgkin lymphomas (Niitsu eta!. , 
2001; Godfried et al. , 2002). 
Although a great deal of progress has been made in creating a more efficient risk group 
classification system, effective treatments for various subsets of patients require new 
markers to aid in advancing the stratification of tumors. Tbdn is highly expressed in the 
most malignant and aggressive subset of neuroblastic tumors. Therefore, additional 
markers will enhance the neuroblastic classification system thereby providing clinicians 
an array of resources for assessing and treating neuroblastic patients. 
5.1.2 Martinet a/., 2009 
Our group, as well as others, showed that MycN expression was down-regulated in 
human neuroblastoma LA-N-5 cells upon RA-induced differentiation (Thiele eta!. , 1985; 
Martin et al. , 2007). I showed that MycN expression correlated with both Tbdn and Ard 1 
expression. In addition, I showed that MycN regulated Tbdn and Ard 1 expression using 
the MYCN-inducible SHEP cell line. One advantage of this well-established cell system 
is that it is inducible which means that the same cell line can be used to over-express or 
suppress MycN expression. One potential drawback of our experimental setup was that I 
did not have access to a second MYCN-inducible cell line to ensure that the regulation of 
Tbdn by MycN was not an artifact of the cell line. However, I did demonstrate that the 
decrease in both Tbdn and Ardl was not cell line dependent. Treatment of the LA-N-5 
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cells with RA, a differentiation agent, resulted in a co-downregulation of Tbdn, Ard 1, and 
MycN. 
The link between aggressiveness of neuroblastoma and MYCN amplification is still 
unclear (Thiele et al. , 1985; Brodeur, 2003; Wei et al., 2008). However, MYCN 
amplification usually leads to high MycN protein and RNA expression in neuroblastomas 
(Tang et al. , 2006). My previous work showed that high levels ofTbdn expression are 
linked with aggressive and high-risk group neuroblastoma and are associated with poor 
survival (Martin et al. , 2007). Our present evidence supports a hypothesis that the 
MycN/Tbdn/Ardl pathway may be regulated in an aberrant manner in neuroblastomas 
with poor outcome. Besides their roles in cancer, Tbdn, Ard 1, and MycN are also 
involved in normal development. Throughout brain development there is a spatia-
temporal up-regulation ofTbdn and Ardl (Sugiura et al., 2003). Similarly, Grady and 
colleagues (1987) showed that MycN was highly expressed in the early fetal cerebral 
germinal layer and the primordial cortex during human fetal brain development (Grady et 
al. , 1987). Therefore, understanding the relationship between TBDN, ARDJ and MycN 
may provide new insight for regulation and treatment of neuroblastoma. 
The MYCN-inducible SHEP cell line was an invaluable tool for studying the potential 
binding of MycN to the TBDN promoter. From our ChiP analysis, I showed that MycN 
binds the TBDN gene (Figure 5-l ). The next step would be to verify our results. I could 
have accomplished this by mutating various nucleotides of the E-box within the promoter 
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region. Another method would be to delete nucleotides within the E-box region. 
However, this would change the size of the E-box region, ultimately affecting basal 
transcription. Therefore, the former option would be the preferred method. Furthermore, 
to determine whether MycN activates transcription of the TBDN gene, luciferase assays 
could have been performed with a number of TBDN promoter I reporter constructs 
containing various point mutations or E-box deletions. This would ultimately determine 
if the TBDN promoter activity directly correlates with MycN expression. In addition, I 
also used the MYCN-inducible system to demonstrate that MycN can regulate Ard 1 
expression. The decrease in Ard 1 expression may result from MycN binding directly to 
Tbdn or MycN may directly bind ARDI through an unknown transcription factor (Figure 
5-l ). 
Tbdn is expressed in the Tet2 MYCN-inducible cell line which lacks MycN expression 
upon tetracycline treatment (see Figure 3-2). The Tet2N MYCN-inducible system cannot 
be completely shut off, even in the presence of tetracycline. Therefore, the Tbdn 
expression present may be a direct result of the low level of MycN expression still being 
expressed. However, an alternative explanation may suggest that other factors could be 
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Figure 5-1. Tbdn, Ardl, and MycN pathway interaction. 
Solid lines represent confirmed interactions whereas dotted lines represent hypothetical 
interactions. 
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involved in regulating Tbdn such as E2F or Hypoxia-inducible factor (Hif). Therefore, I 
suggested a hypothetical model to explain the potential interactions between Tbdn, Ard 1, 
and MycN (Figure 5-l ). 
Hypoxia can drive solid tumors towards an immature phenotype (Axelson et al., 2005). 
Poorly oxygenated environments express transcription factors such as Hif-1 and Hif-2 
(Nilsson et al. , 2005; Lofstedt et al., 2007). Before discussing the role ofHifs with the 
Tbdn/ Ard 1 complex, it is important to first describe the relationship between the 
Tbdn/Ard1 complex, in particular, Ardl and the Wnt signaling pathway. 
The NatA complex appears to target the Wnt signaling pathway. As mentioned, during 
normal neuro-ectodermal development, an anomaly results in the formation of 
neuroblastoma (Brodeur, 2003; van Noesel and Versteeg, 2004; Maris, 2005; Vasudevan 
eta!., 2005). One of the earliest pathways involved in neuro-ectodermal development is 
the Wnt signaling pathway. Recently, Lim and colleagues demonstrated that Ardi is 
responsible for acetylating and activating the ~-Catenin pathway and promoting cancer 
proliferation (Figure 5-2; Lim et al., 2006). In addition, Wai et al. also reported an up-
regulation of wingless-type mouse mammary tumor virus integration site family member 
11 (WNT11) in neuroblastoma cells (Wai et al. , 2002). Acetylation of ~-Catenin induces 
the binding of TCF 4 to the cyclin D I promoter. hArd !-silencing RNA was used to treat 
lung cancer cells, resulting in inhibition of cell proliferation and induction of G I arrest 
(Lim et al., 2006). A ChiP assay was used to demonstrate that silencing ofhArdi 
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Figure 5-2. Possible mechanism of NatA acetylating Beta-Catenin. 
An increase in the activity of Beta-Catenin through NatA acetylation results in an 















inhibited the recruitment of ~-Catenin/TCF complex on the cyclin D 1 promoter. Since 
p300 was also known to active ~-Catenin by acetylation, Lim et al. wanted to 
demonstrate that p300 did not affect the association between ~-Catenin and Ard 1. 
siRNA-p300 knockdown revealed an attenuation of p300 binding for ~-Catenin but did 
not affect the association between Ard 1 and ~-Catenin. 
Therefore, p300 knockdown was shown not to be necessary for the interaction between 
hArd 1 and ~-Catenin. However, both the siRNA-Ard 1 and the siRNA-p300 knockdowns 
inhibited ~-Catenin acetylation independently of each other (Lim et al., 2006). 
Collectively, the above mentioned studies indicate that Ard 1 has a role in cellular growth. 
Under hypoxic conditions, Hif-1a binds hArdl and in the process dissociates hArd1 from 
~-Catenin thereby preventing hArd1 from acetylating ~-Catenin (Figure 5-2; Lim et al. , 
2008). Specifically, the deacetylation of ~-Catenin, through hArd1 removal, will 
ultimately repress that transcriptional activity of the ~-Catenin/TF complex and down-
regulate c-Myc by disrupting the ~-Catenin/TF complex. Moreover, knocking down Hif-
la augments ~-Catenin acetylation, resulting in activation of target genes such as c-Myc 
(Lim et al., 2008). In addition, Hif-1a has been reported to bind directly to ~-Catenin and 
down-regulate c-Myc expression (Figure 5-2; Kaidi et al., 2007; Lim et al., 2008). 
During prolonged hypoxia there is a notable difference between Hif-1 a and Hif-2a in 
neuroblastoma. The Hif-2a protein levels tend to accumulate whereas Hif-1a protein 
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levels are reduced or disappear over time (Holmquist-Mengelbier et al., 2006; Lofstedt et 
al. , 2007). The Hif-2 accumulation in neuroblastoma correlates with advanced stages and 
low patient survival. Poorly vascularized solid tumors such as neuroblastomas become 
de-differentiated and more aggressive under hypoxic conditions (Nilsson et al. , 2005). In 
addition, neuroblastoma twnor evaluation revealed a strong correlation between high Hif-
2 levels and unfavorable patient outcome (Holmquist-Mengelbier et al., 2006). 
Holmquist-Mengelbier and colleagues used a xenograft model to demonstrated that 
knocking down Hif-2 resulted in decreased growth of neuroblastoma (Holmquist-
Mengelbier et al., 2006). Since the TBDN promoter region contains three HREs (Figure 
3-3), and is up-regulated in the less differentiated cancers, it becomes tempting to 
speculate that Hif-2 would bind HRE and induce Tbdn expression, resulting in an 
increase in the growth of neuroblastoma. 
5.1.3 Tbdn, Ard1, Myc, and Cancer 
As mentioned, neuroblastoma has a wide range of heterogeneity with respect to 
differentiation, possibly caused by hypoxic conditions (Jogi et al., 2002; Brodeur, 2003). 
In addition, factors such as MycN also play a role in neuroblastoma growth and 
differentiation (Vita and Henriksson, 2006). Why then is it important to study Tbdn? 
Tbdn is involved in tumorigenesis (Arnesen et al., 2006c). Knocking down Tbdn 
expression in HeLa cells by siRNA technology resulted in a decrease in cell viability by 
increasing the rate of apoptosis (Arnesen eta!., 2006c ). Tbdn is highly expressed in 
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cancers such as neuroblastoma, papillary thyroid carcinomas, gastric cancer, and Burkitt 
lymphoma. A commonality between these tumor types is their high rates of proliferation. 
Tbdn is up-regulated in neoplastic thyroid tissue versus non-neoplastic thyroid tissue 
indicating that the higher levels of the Tbdn protein may provide a growth advantage for 
the cancer cells (Arnesen et al. , 2005b). In addition, our laboratory showed that high 
Tbdn levels are found in the advanced stages of neuroblastoma specimens compared to 
the less aggressive stages (Martinet al., 2007). Possible mechanisms for such regulation 
of cellular growth and differentiation in cancer cells may involve the action of Nat I I Ard l 
as a factor acetyltransferase, or uncharacterized activities of Tbdn protein. In particular, 
I have reported that MycN can bind and regulate the expression ofTbdn (Figure 3-2 & 3-
4). 
In addition to MycN, Myc also appears to be linked to Tbdn expression. Tbdn has been 
shown to regulate cell growth in cervical (HeLa) cells that over-express both Tbdn and c-
Myc (Arnesen et al. , 2006c). Similar to HeLa cells, Ewing sarcoma cells also over-
express both Tbdn and c-Myc (Parham, 1996; Macville et al. , 1999; Henriksson et al. , 
2001; Rorie et al. , 2004; H. Paradis, personal communication). Knocking down Tbdn in 
this cell model resulted in a decrease in cell growth (in vitro) and tumor growth (in vivo) 
(H. Paradis, personal communication). 
c-MYC and MYCN are conserved genes belonging to the san1e family. Knockout models 
of either gene results in embryonic lethality (Nesbit et al., 1999). In addition, c-Myc and 
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MycN are transcription factors that dimerize to Max and bind to the same E-box 
(CACGTG) consensus sequence (Blackwell et a!., 1990; Blackwood and Eisenman, 
1991). Although both c-Myc and MycN have oncogenic potential, they are involved in 
different tumor types. c-Myc is generally involved in tumors such as epithelial cervix 
adenocarcinoma whereas MycN is involved mainly with neuroblastoma (Ben-Yosef et 
a!., 1998). Furthermore, based on the results from our group and others (Arnesen eta!. , 
2008), it is tempting to speculate that Myc may regulate Tbdn and/or Ardl in other 
cancer models. 
Tbdn and Cytogenetic Aberrations 
In addition to MycN, other factors such as cytogenetic aberrations may explain the 
pathobiology of neuroblastomas. In particular, the allelic loss of chromosome 4p was 
found in 20% of neuroblastomas irrespective of disease stage, patient age, loss of 
heterozygosity I p or MYCN amplification (Caron eta!., 1996a). Therefore, the allelic 
loss of 4p may impact upon neuroblastoma pathobiology (McGowan-Jordan et a!., 1994; 
van Noesel and Versteeg, 2004). More recently, Gisselsson eta!. completed a 
retrospective study using karyotypes from the Mitelman Database of Chromosome 
Aberrations in Cancer. Gisselsson and colleagues demonstrated whole chromosome 4 
loss in low-stage and low-risk neuroblastoma tumors (Gisselsson et al., 2007). Tbdn is 
located at 4p31 .1 and our laboratory reported that low levels of Tbdn expression are 
found in the low-stage and low-risk group (Martinet a!., 2007). It is tempting to 
speculate that loss of chromosome 4 may delete Tbdn . 
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Recently, Tbdn was found in a complex with the actin binding protein cortactin in retinal 
endothelial cells (Paradis eta!., 2008). Our laboratory has previously shown that Tbdn 
exerts a homeostatic influence in retinal endothelial cells although we have not yet 
identified in vivo acetyl transferase substrates of the Tbdn complex (Wall et al. , 2004; 
Paradis et a!., 2008). While these findings provide insight into understanding the nature 
of the Tbdn complex, they also raise the intriguing question of whether Tbdn associates 
with cortactin in neuroblastoma cells. Cortactin is also involved in the process of tumor 
progression and metastasis formation. Cortactin has been reported to be over-expressed 
in breast cancers as well as head and neck cancers (Buday and Downward, 2007). In 
addition, amplification of cortactin has been found to occur in aggressive head and neck 
squamous cell carcinoma (Clark eta!. , 2008), as well as a subgroup of neuroblastoma 
(Michels eta!., 2007). Therefore, it is tempting to speculate that the association between 
cortactin and the Tbdn complex may contribute to the aggressiveness of the NTs. 
5.1.4 Pitfalls & Future Directions 
Although I was unable to silence Tbdn expression in neuroblastoma (LA-N-5) cells using 
siRNA technology, I knocked-down Tbdn expression in other cell models such as rhesus 
macaque choroid-retina endothelial (RF/6A) cells. In addition, Arnesen and colleagues 
silenced Tbdn expression in epithelial cervical adenocarcinoma (HeLa) cells (Arnesen et 
a!. , 2006c). However, there are many reasons for not getting a decrease in Tbdn 
expression in the LA-N-5 cells using siRNA technology. Firstly, the optimal siRNA 
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sequence may not have been selected. Again, the only way to truly determine the optimal 
siRNA sequence is by experimental testing. Secondly, suppression ofTbdn alone may 
not show an effect on neuroblastoma cells since the co-interacting Ard 1 acetyl transferase 
may be limiting. In addition, our laboratory was also interested in over-expressing Tbdn 
to determine if neuroblastoma cells would become more malignant with increased levels 
of Tbdn expression. Many unsuccessful attempts to over-express Tbdn have been made 
by our laboratory. Again, over-expression of Tbdn alone may not show an effect on 
neuroblastoma cells since the co-interacting Ardl acetyltransferase may be limiting. 
Over-expression of either Tbdn or Ardl alone is not sufficient to result in an increase in 
acetyltransferase activity. Therefore, both Tbdn and Ardl must be over-expressed to 
attain an increase in the acetyltransferase activity (Mullen et al. , 1989; Arnesen eta!., 
2006c; Arnesen et a!. , 2008). 
A decrease in Tbdn and MycN expression was observed upon RA-induced differentiation 
of neuroblastoma cells (Thiele et al. , 1985; Martinet a!., 2007). To confirm the link 
between Tbdn, MycN, and differentiation, a MycN inducible system could be utilized. 
Unfortunately, the MYCN-inducible SHEP system generated by Lutz eta!. (1996) would 
not be an effective model to study the putative effects of MYCN on differentiation (Edsjo 
et al. , 2004). The problem with using the MycN-induced SHEP model is that the SHEP 
cell line is an S-type cell line and not anN-type. Treatment of the S-type cells with a 
differentiation agent such as RA would induce apoptosis instead of neuronal elongation 
(Voigt and Zintl, 2003). Subsequent to RA treatment, N-type cells elongate their 
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neuronal processes, reminiscent of axons or dendrites. However, S-type of cells lose 
their adherence to substratum and become apoptotic (Voigt and Zintl, 2003). Edsjo et al. 
over-expressed MycN in a SK-N-SH (N-type) cell line resulting in a SKMYC2 cell line 
that constitutively expressed MYCN (Edsjo et al., 2004). However, the downfall with 
this system is the lack of inducibility or regulation. Similarly, Slack et al. cloned MycN 
eDNA into a subclone of the SHEP cell line but again the cell line was epithelial-like 
(Slack eta!., 2005). Ideally, generating an inducible MycN system, in anN-type of cell 
that has the potential to differentiate would be the preferred model. 
As alluded earlier, I generated an in vitro conditional knockdown system to exan1ine the 
effects of Tbdn knockdown on neuroblastoma growth and differentiation. I planned on 
using these knockdown clones to complete preclinical work. A xenograft mouse model 
would have been used to determine if decreased Tbdn levels would have an effect on 
tumor growth or tumor differentiation. Three different approaches include giving 
Doxycycline to cells in vitro then injecting the cells into the nude mice; injecting the non-
induced cells into the mice then letting the tumor grow before giving the mice 
Doxycycline to determine if the tumor decreased in size; and removing Doxycycline from 
the diet of the mouse to determine if the tumor reappears. The expected outcome would 
be that knockdown of Tbdn expression may decrease or stabilize tumor growth and shift 
the level of tumor differentiation toward a more differentiate form . Unfortunately, there 
were many issues regarding the leakiness with this inducible system. Therefore, further 
experiments using this model system could not be completed. 
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Another focus of my work involves MycN, as alluded to earlier, is an important factor 
surrounding the aggressivity of neuroblastoma. Since my in vitro data suggests that 
MycN regulates Tbdn expression, I would be interested in determining in vivo if varying 
levels of MycN expression affects Tbdn expression. Could this outcome influence tumor 
progression? Before determining the effects of MycN on Tbdn expression in vivo, I will 
need an inducible MycN mouse model. William Weiss and colleagues have generated a 
transgenic mouse model that over-expresses MycN in the neuroectodermal cells, 
resulting in development of neuroblastoma (Weiss eta!., 1997). To target MYCN 
expression to the neural crest cells, Weiss and colleagues used a tyrosine hydroxylase 
promoter. The tyrosine hydroxylase promoter is active in migrating cells and targets 
catecholamine neurons during early development (Banerjee eta!., 1992). Weiss eta!. 
demonstrated that tumor formation is dependent on MYCN gene dosage. Homozygotes 
were reported to have increased incidence and decreased latency of tumor formation 
(Weiss eta!. , 1997). 
I would be interested in determining if there is a relationship between MYCN gene 
dosage, Tbdn activation, and tumor formation. By varying the levels of MycN 
expression I would expect to get varying levels ofTbdn activation. This would ultimately 
result in the generation of neuroblastoma tumors that varied in size and complexity. I 
would expect that high levels of MycN would drive Tbdn activation and result in the 
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generation of poorly differentiate tumors whereas low MycN expression would only 
weakly activate Tbdn and result in no tumor or a more differentiated tumor. 
These future experiments will help define the functional role that Tbdn plays in NT 
progression/development. In particular, the above mentioned experiments will determine 
whether Tbdn expression drives neuroblastoma growth and whether MycN regulates 
neuroblastoma growth through Tbdn expression using in vivo models. 
5.1.5 Potential Tubedown Mechanism 
My hypothetical Tbdn mechanism (Figure 5-3) is based on a deregulated Wnt/P-Catenin 
pathway that is found in high risk neuroblastoma without MYCN amplification (Liu et al., 
2008). Wnt/P-Catenin signaling may be of particular relevance to neuroblastomas, 
arising from highly migratory neural crest stem cells (Dyer, 2004; Mora and Gerald, 
2004 ). There are subsets of high-risk neuroblastomas without MYCN an1plification that 
have high MycN expression (Suenaga et al., 2009). MYCN mRNA is expressed at high 
levels in some subsets of neuroblastoma with only a single copy of the MYCN gene. This 
is accomplished by positive auto-regulation of MycN in human neuroblastomas. MycN 
protein enhances its own promoter activity through direct recruitment onto the intron 1 






r Target genes: 
Cyclin 01 
Figure 5-3. Possible mechanism of Tubedown. 
Subsets of high-risk neuroblastomas without MYCN amplification can have high MycN 
expression that will potentially drive the expression of the Tbdn complex thereby 
acetylating Beta-Catenin and resulting in an increase in cellular proliferation. 
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High expression of the MycN protein will bind to the E-box located in the TBDN 
promoter region. Increased expression of the Tbdn/Ardl complex will drive the 
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